UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ |
|
Preliminary Proxy Statement |
|
|
☐ |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
|
☒ |
|
Definitive Proxy Statement |
|
|
☐ |
|
Definitive Additional Materials |
|
|
☐ |
|
Soliciting Material under §240.14a-12 |
PHIO PHARMACEUTICALS CORP.
(Name of Registrant as Specified In Its Charter)
N/A
(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
|
|
|
|
|
☒ |
|
No fee required. |
|
|
☐ |
|
Fee paid previously with preliminary materials. |
|
|
|
☐ |
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
257 Simarano Drive, Suite 101
Marlborough, MA 01752
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on July 20, 2023
Dear Stockholder:
You are cordially invited to attend the 2023 Annual Meeting of Stockholders
(the “Annual Meeting”) of Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), which
will be held on July 20, 2023, at 9:00 a.m. (Eastern Time). The meeting will be a completely virtual meeting of stockholders. You can
attend the meeting by visiting meetnow.global/MQKLG2L where you will be able to listen to the meeting live, submit questions, view the
stockholder list, and vote online. Because the meeting is completely virtual and being conducted via the internet, stockholders will not
be able to attend the meeting in person physically.
Only stockholders who held common stock at the close of business on
the record date, May 30, 2023, may vote at the Annual Meeting, including any adjournment or postponement thereof. At the Annual Meeting,
you will be asked to consider and vote upon:
|
(1) |
the election of the five director nominees named in the accompanying Proxy Statement; |
|
(2) |
the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023; |
|
(3) |
an amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 125,500; and |
|
(4) |
the transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained. |
The accompanying Proxy Statement more fully describes the details of
the business to be conducted at the Annual Meeting. After careful consideration, the Board of Directors has unanimously approved the proposals
and recommends that you vote FOR each nominee and proposal described in the Proxy Statement.
We are pleased to make use of the Securities and Exchange Commission
(the “SEC”) rules that allow companies to furnish proxy materials to their stockholders via the internet. We believe
the ability to deliver proxy materials electronically allows us to provide our stockholders with the information they need, while lowering
the costs of delivery and reducing the environmental impact from the distribution of our Annual Meeting materials.
We look forward to seeing you at the Annual Meeting.
|
Sincerely, |
|
|
|
/s/Robert Bitterman |
|
Robert Bitterman |
|
President and Chief Executive Officer |
June 9, 2023
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING,
PLEASE VOTE VIA THE INTERNET, OVER THE TELEPHONE OR BY MAIL BY FOLLOWING THE INSTRUCTIONS FOUND ON THE NOTICE REGARDING THE AVAILABILITY
OF PROXY MATERIALS OR ON THE ENCLOSED PROXY CARD AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR REPRESENTATION AT THE MEETING.
EVEN IF YOU HAVE VOTED BY PROXY, YOU MAY STILL VOTE AT THE MEETING IF YOU ATTEND THE MEETING VIRTUALLY. PLEASE NOTE, HOWEVER, THAT IF
YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND YOU WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN A LEGAL PROXY FROM
THAT INTERMEDIARY.
257 Simarano Drive, Suite 101
Marlborough, MA 01752
PROXY STATEMENT FOR
2023 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JULY 20, 2023
GENERAL INFORMATION
This Proxy Statement is furnished in connection with the solicitation
of proxies by the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (“Phio,” the “Company,”
“we,” “us” or “our”) for use at the Company’s 2023 Annual Meeting of Stockholders
(the “Annual Meeting”). The Company will hold the Annual Meeting virtually on Thursday, July 20, 2023 at 9:00 a.m.
(Eastern Time). You can attend the Annual Meeting by visiting meetnow.global/MQKLG2L, where you will be able to listen to the meeting
live, submit questions and vote online. To participate in the Annual Meeting, you will need the control number included on your Notice
Regarding the Availability of Proxy Materials (the “Notice”), the proxy card or on the instructions that accompanied
your proxy materials. Because the Annual Meeting is completely virtual and being conducted via the internet, stockholders will not be
able to attend the meeting in person physically.
The Company anticipates that
the Notice will first be mailed on or about June 9, 2023 to all stockholders entitled to vote at the Annual Meeting and we will post our
proxy materials on the website referenced in the Notice. The Notice instructs you as to how you may access and review important
information contained in the proxy materials. The Notice also instructs you on how you may submit your proxy via the internet, or, if
you chose to request paper copies of proxy materials, the instructions for how you may submit your proxy can be found on the proxy card,
or on the instructions that accompanied your proxy materials. If you receive a Notice by mail and would like to receive a printed copy
of our proxy materials, you should follow the instructions for requesting such materials included in the Notice.
For a proxy to be effective, it must be properly executed and received
prior to the Annual Meeting. Each proxy properly tendered will, unless otherwise directed by the stockholder, be voted for the proposals
and nominees described in this Proxy Statement and at the discretion of the proxy holder(s) with regard to all other matters that may
properly come before the meeting.
The Company will pay all of the costs of soliciting proxies. We will
provide copies of our proxy materials to brokerage firms, fiduciaries and custodians for forwarding to beneficial owners who request printed
copies of these materials and will reimburse these persons for their costs of forwarding these materials. Our directors, officers and
employees may also solicit proxies by telephone, email or personal solicitation; however, we will not pay them additional compensation
for any of these services.
Shares Outstanding and Voting Rights
Only holders of record of the Company’s common stock, par value
$0.0001 per share (the “Common Stock”) at the close of business on May 30, 2023 (the “Record Date”),
are entitled to notice of and to vote at the Annual Meeting. On the Record Date, 1,504,565 shares of Common Stock were issued and outstanding.
Each share of Common Stock is entitled to one vote on all matters to be voted upon at the Annual Meeting. Holders of Common Stock do not
have the right to cumulative voting in the election of directors. The presence, in person virtually or by proxy, of the holders of at
least one-third of the outstanding shares on the Record Date will constitute a quorum for the transaction of business at the Annual Meeting
and any adjournment or postponement thereof.
Persons who hold shares of our Common Stock directly on the Record
Date (“record holders”) must vote via the internet or telephone, return a proxy card by mail or attend the Annual Meeting
in person virtually in order to vote on the proposals. Persons who hold shares of our Common Stock indirectly on the Record Date through
a brokerage firm, bank or other financial institution (“beneficial holders”) must return a voting instruction form
to have their shares voted on their behalf. Brokerage firms, banks or other financial institutions that do not receive voting instructions
from beneficial holders may, unless prohibited by each brokerage firm’s, bank’s or other financial institution’s internal
policies, either vote these shares on behalf of the beneficial holders on certain “routine” matters or return a proxy leaving
these shares un-voted (a “broker non-vote”). Many brokerage firms, such as Charles Schwab and TD Ameritrade, have recently
decided to eliminate discretionary voting even for “routine” matters, making it increasingly difficult to obtain the majority
voting power of the issued and outstanding shares of Common Stock necessary to pass certain “routine” matters.
Abstentions and broker non-votes (if any) will be counted for the purpose
of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on
a given proposal. The required vote for each of the proposals expected to be acted upon at the Annual Meeting is described below:
Proposal No. 1 — Election of directors. Directors are
elected by a plurality, with the five nominees obtaining the most votes being elected. Because there is no minimum vote required, votes
withheld and broker non-votes (if any) will be entirely excluded from the vote and will have no effect on its outcome.
Proposal No. 2 — Ratification of independent registered public
accounting firm. This proposal must be approved by a majority of the votes cast on the matter. As a result, abstentions and broker
non-votes (if any) will be entirely excluded from the vote and will have no effect on its outcome.
Proposal No. 3 — Approval of an amendment and restatement
of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance
thereunder by 125,500. This proposal must be approved by a majority of the votes cast on the matter. As a result, abstentions and
broker non-votes (if any) will be entirely excluded from the vote and will have no effect on its outcome.
We encourage you to vote by proxy, whether via telephone, through the
internet or mailing an executed proxy card. By voting in advance of the Annual Meeting, this ensures that your shares will be voted and
reduces the likelihood that the Company will be forced to incur additional expenses soliciting proxies for the Annual Meeting. Any record
holder of our Common Stock may attend the Annual Meeting in person virtually and may revoke the enclosed form of proxy at any time by:
|
· |
|
executing and delivering to the Corporate Secretary a later-dated proxy; |
|
|
|
|
|
· |
|
delivering a written revocation to the Corporate Secretary before the meeting; or |
|
|
|
|
|
· |
|
voting in person virtually at the Annual Meeting. |
Beneficial holders of our Common Stock who wish to change or revoke
their voting instructions should contact their brokerage firm, bank or other financial institution for information on how to do so. Beneficial
holders who wish to attend the Annual Meeting and vote in person virtually should contact their brokerage firm, bank or other financial
institution holding shares of our Common Stock on their behalf in order to obtain a “legal proxy,” which will allow them to
both attend the Annual Meeting and vote in person virtually. Without a legal proxy, beneficial holders cannot vote at the Annual Meeting
because their brokerage firm, bank or other financial institution may have already voted or returned a broker non-vote on their behalf.
Virtually Attending the Annual Meeting
You will be able to attend the Annual Meeting online, submit your questions
during the meeting and vote your shares electronically at the meeting by visiting meetnow.global/MQKLG2L. Because the Annual Meeting is
completely virtual and being conducted via the internet, stockholders will not be able to attend the meeting in person physically. However,
we have designed the meeting to provide stockholders with the same rights and opportunities to participate as they would have at an in-person
meeting. To participate in the Annual Meeting, you will need the control number included on your Notice, proxy card or on the instructions
that accompanied your proxy materials. If you hold your shares through an intermediary, such as a bank or broker, you must register in
advance using the instructions below. The Annual Meeting webcast will begin promptly at 9:00 a.m. (Eastern Time). We encourage you to
access the meeting prior to the start time. Online check-in will begin at 8:50 a.m. (Eastern Time), and you should allow ample time for
the check-in procedures.
We expect that the virtual meeting platform will be supported across
Microsoft Edge, Firefox, Chrome and Safari browsers and devices (desktops, laptops, tablets and cell phones) running the most up-to-date
version of applicable software and plugins. Please note that Internet Explorer is no longer supported. Participants should ensure that
they have a strong WiFi connection wherever they intend to participate in the meeting. A link on the meeting page will provide further
assistance should you need it or you may call 1-888-724-2416 or 1-781-575-2748.
If you are a registered shareholder (i.e. you hold your shares through
our transfer agent, Computershare Trust Company, N.A. (“Computershare”)), you do not need to register to attend the
Annual Meeting virtually on the internet. Please follow the instructions on the Notice or proxy card that you received.
If you hold your shares through an intermediary, such as a bank or
broker, you must register in advance to attend the Annual Meeting virtually on the internet. To register to attend the Annual Meeting
online by webcast you must submit proof of your proxy power (legal proxy) reflecting your Company holdings along with your name and email
address to Computershare. Requests for registration must be labeled as “Legal Proxy” and be received no later than 5:00 p.m.,
Eastern Time, on July 12, 2023. You will receive a confirmation of your registration by email after we receive your registration materials.
Requests for registration should be directed by: (i) email to legalproxy@computershare.com, with a forward of the email from your broker,
or attach an image of your legal proxy; or (ii) mail to Computershare, Phio Pharmaceuticals Corp. Legal Proxy, P.O. Box 43001, Providence,
Rhode Island 02940-3001.
You may submit questions at the Annual Meeting through any of the following
methods:
Prior to the Annual Meeting, by logging on to meetnow.global/MQKLG2L
using the control number included on your Notice, proxy card or on the instructions that accompanied your proxy materials or accessing
the site via your email. You can then click on the “Messages” icon on the right-hand side of the page. A pop-up window will
appear where you may type your question in the text box. Once done, click “Submit” to submit your question, after which a
confirmation message will be displayed.
During the Annual Meeting, by accessing the meeting website above using
the control number included on your Notice, proxy card or on the instructions that accompanied your proxy materials. You can then submit
a live text question by clicking the “Messages” icon on the right-hand side of the page where you may type your question in
the text box by typing in the “Ask a Question” box.
PROPOSAL NO. 1
ELECTION OF DIRECTORS
The Amended and Restated Bylaws of the Company (the “Bylaws”)
provide that the number of directors shall be fixed solely by resolution adopted from time to time by a majority of the directors then
in office. The total Board size is currently fixed at six directors, however the Board has, by duly adopted resolution, decreased the
size of the Board to five directors, effective at the beginning of the Annual Meeting. Currently, the directors (whose terms expire at
the Annual Meeting) are Robert J. Bitterman, Patricia A. Bradford, Geert Cauwenbergh, Dr. Med. Sc., Robert L. Ferrara, Jonathan E. Freeman,
Ph.D. and Curtis A. Lockshin, Ph.D. Dr. Cauwenbergh will not be standing for reelection at the 2023 Annual Meeting.
As described below, the Board has nominated Drs. Freeman and Lockshin,
Ms. Bradford, and Messrs. Bitterman and Ferrara for reelection, as directors at the Annual Meeting. All nominees were most recently elected
by stockholders at the 2022 Annual Meeting and have indicated their willingness to serve if elected. Each Director elected at the Annual
Meeting will hold office until the 2024 Annual Meeting of Stockholders and until such Director’s successor is elected and qualified,
unless such Director resigns or such Director’s seat become vacant due to death, removal or other cause in accordance with the Bylaws.
Should any nominee become unavailable for election at the Annual Meeting, the Board may reduce its size.
Nomination of Directors
The Nominating Committee of the Board (the “Nominating Committee”)
reviews and recommends to the Board potential nominees for election to the Board. In reviewing potential nominees, the Nominating Committee
considers the qualifications of each potential nominee in light of the Board’s existing and desired mix of experience and expertise.
The Nominating Committee considers many factors when making a determination to nominate a candidate for a director position on the Board,
such as integrity and character, prior business experience, including experience relating to the biotechnology industry, financial literacy
and the nominee’s willingness to commit substantial time to the Company. After reviewing the qualifications of potential Board candidates,
the Nominating Committee presents its recommendations to the Board, which selects the final director nominees. Upon the recommendation
of the Nominating Committee, the Board nominated Drs. Freeman and Lockshin, Ms. Bradford and Messrs. Bitterman and Ferrara for reelection.
The Company did not pay any fees to any third parties to identify or assist in identifying or evaluating nominees for the Annual Meeting.
The Nominating Committee considers stockholder nominees using the same
criteria set forth above. Stockholders who wish to present a potential nominee to the Nominating Committee for consideration for election
at a future annual meeting of stockholders must provide the Nominating Committee with notice of the nomination and certain information
regarding the candidate within the time periods set forth below under the caption “Stockholder Proposals.”
Directors Nominated for Election
The Nominating Committee has recommended and the Board has nominated
Drs. Freeman and Lockshin, Ms. Bradford and Messrs. Bitterman and Ferrara to be reelected as directors at the Annual Meeting. The following
table sets forth the following information for these nominees: the year each was first elected a director of the Company; their respective
ages as of the date of filing of this Proxy Statement; the positions currently held with the Company, if any, and the year their current
term will expire, if applicable:
Nominee / Director Name
and Year First Became a Director |
|
Age |
|
Position(s) with
the Company |
|
Year Current
Term Expires |
|
Nominees for Directors: |
|
|
|
|
|
|
|
Robert J. Bitterman (2012) |
|
72 |
|
Chair of the Board of Directors, President and Chief Executive Officer of the Company |
|
2023 |
|
Patricia A. Bradford (2022) |
|
72 |
|
Director |
|
2023 |
|
Robert L. Ferrara (2019) |
|
72 |
|
Lead Independent Director |
|
2023 |
|
Jonathan E. Freeman, Ph.D. (2017) |
|
55 |
|
Director |
|
2023 |
|
Curtis A. Lockshin, Ph.D. (2013) |
|
62 |
|
Director |
|
2023 |
|
Robert J. Bitterman has
served as a member and the Chair of the Board since 2012 and as our President and Chief Executive Officer since February 2023. Mr. Bitterman
served as the Interim Executive Chair of the Company from September 2022 to February 2023 until his appointment as President and Chief
Executive Officer. Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company
he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue,
until its acquisition by Biofrontera, Inc., USA in March 2019. Since leaving Cutanea, Mr. Bitterman was retired until commencing the Interim
Executive Chair role with the Company in September 2022. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman also held the
position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various
positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in
Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor
of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine. Our Nominating Committee believes that Mr. Bitterman
is qualified to serve as a member of the Board due to his executive leadership experience and his experience in the pharmaceutical industry.
Patricia A. Bradford has served
as a member of the Board since 2022. Ms. Bradford served as Senior Vice President Global Human Resources at Unisys Corporation, a global
information technology solutions company, where her total service at Unisys spanned from 1982 until her retirement in 2013. In her role
at Unisys, Ms. Bradford strategically led all global human resource programs and initiatives, including talent management, at multiple
levels of the organization. Ms. Bradford’s roles at Unisys progressively included all areas of human resources, including an overseas
assignment at the Unisys European headquarters where she provided human resources leadership to the region. Prior to Unisys, Ms. Bradford
was employed by Deloitte, an audit, consulting, tax, and advisory services firm, from 1978 to 1982. Since 2014, Ms. Bradford has maintained
a consulting practice focused on individual coaching for senior executives and high potential employees recommended by management. Ms.
Bradford received a B.S. degree with an emphasis on accounting and statistics from Walsh College and is a Certified Public Accountant.
Our Nominating Committee believes that Ms. Bradford is qualified to serve as a member of the Board due to her executive leadership experience,
global business perspective, and human capital management and financial backgrounds.
Robert L. Ferrara has
served as a member of the Board since 2019 and currently serves as our Lead Independent Director.
He most recently served as the Chief Financial Officer of Cutanea Life Sciences, Inc., a private company focused on developing innovative
technologies to treat diseases and disorders of the skin and subcutaneous tissue, from January 2012 to his retirement in June 2019. Prior
to Cutanea, Mr. Ferrara served as the Chief Financial Officer of Storeroom Solutions Inc., a venture capital financed, technology enhanced,
integrated supply chain solutions company, from 2004 to 2011, and NER Data Products, Inc., an IT service management company, from 2000
to 2003, as well as holding other senior level financial positions in national and international public companies in the greater Philadelphia
area. Mr. Ferrara received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant. Our Nominating Committee
believes that Mr. Ferrara is qualified to serve as a member of the Board due to his financial expertise and his extensive experience in
both publicly traded and venture capital backed companies in a variety of industries, including the life sciences.
Jonathan E. Freeman, Ph.D. has
served as a member of the Board since 2017. Dr. Freeman currently serves as the Chief Operating
Officer of Anthos Therapeutics Inc., a clinical-stage biopharmaceutical company developing therapies for cardiovascular patients, a position
he has held since July 2021. Anthos Therapeutics Inc. was launched by Novartis and Blackstone Life Sciences, a private investment firm,
where Dr. Freeman has also served as a Senior Advisor since July 2018. From 2017 to June 2018, Dr. Freeman held the position of Chief
Business Officer of Vedanta Biosciences, a clinical-stage company developing therapies for immune-mediated diseases. Prior to his role
with Vedanta Biosciences, Dr. Freeman was the Senior Vice President of Strategy and Portfolio Management and Head of Business Development
and Licensing at Merck KGaA, a leading science and technology company, from 2008 to 2016. Dr. Freeman received a Ph.D. in Molecular Pharmacology
and Drug Metabolism from the Imperial Cancer Research Fund (now CRUK), an M.A. and First Class Honours in Biochemistry from Cambridge
University and a MBA with a finance major from Webster University, St. Louis. Our Nominating Committee believes that Dr. Freeman
is qualified to serve as a member of the Board due to his executive leadership experience and his background in immunology.
Curtis A. Lockshin, Ph.D. has served as a member of the
Board since 2013. Dr. Lockshin currently serves as the Chief Scientific Officer of Xenetic Biosciences, Inc., a biopharmaceutical company
focused on the development of novel oncology therapeutics, a position he has held since January 2017. Prior to this appointment, Dr. Lockshin
served as Xenetic Biosciences, Inc.’s Vice President of Research and Operations from March 2014 to January 2017. From July 2016
to December 2016, Dr. Lockshin served as Chief Technical Officer of VBI Vaccines, Inc., a company developing vaccines in infectious disease
and immuno-oncology. VBI Vaccines, Inc. merged with SciVac Therapeutics, Inc. and its subsidiary SciVac, Ltd., a commercial-stage biologics
and vaccine company, in July 2016 where Dr. Lockshin had served as its Chief Executive Officer and director since September 2014. Since
2004, Dr. Lockshin has served as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation.
Since May 2013, Dr. Lockshin has also served as President and Chief Executive Officer of Guardum Pharmaceuticals, LLC, a private pharmaceutical
company. Dr. Lockshin holds a S.B. degree in Life Sciences and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.
Our Nominating Committee believes that Dr. Lockshin is qualified to serve as a member of the Board due to his scientific background, his
significant industry knowledge and management experience.
Vote Required
The five nominees who receive the greatest number of affirmative votes
of the shares cast will be elected as directors. Any shares that are not voted, whether by votes withheld, broker non-votes (if any) or
otherwise, will not affect the election of directors. Holders of proxies solicited by this Proxy Statement will vote the proxies received
by them as directed on the proxy card or, if no direction is made, then FOR the election of the nominees named in this Proxy Statement.
THE BOARD RECOMMENDS A VOTE “FOR”
EACH OF THE NOMINEES IDENTIFIED ABOVE.
CORPORATE GOVERNANCE
Code of Business Conduct and Ethics
We have adopted a Code of Business
Conduct and Ethics that applies to all employees, officers and directors. Our Code of Business Conduct and Ethics, as well as other corporate
governance materials, is located on our website at www.phiopharma.com. Waivers of our Code of Business Conduct and Ethics
may only be granted by the Board. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct
and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K within four business days
following the date of such amendment or waiver.
Board Diversity
Although the Nominating Committee considers whether nominees assist
in achieving a mix of Board members that represents a diversity of background and experience, including but not limited to race, gender
or national origin, we have no formal policy regarding Board diversity. The Nominating Committee assesses its effectiveness in achieving
these goals in the course of assessing director candidates, which is an ongoing process.
Provided below is a board diversity matrix chart pursuant to Nasdaq’s
Board Diversity Rule.
Board Diversity Matrix (As of May 30, 2023) |
Total Number of Directors |
6 |
|
Female |
Male |
Non-Binary |
Did Not
Disclose
Gender |
Part I: Gender Identity |
Directors |
1 |
5 |
0 |
0 |
Part II: Demographic Background |
African American or Black |
0 |
0 |
0 |
0 |
Alaskan Native or Native American |
0 |
0 |
0 |
0 |
Asian |
0 |
0 |
0 |
0 |
Hispanic or Latinx |
0 |
0 |
0 |
0 |
Native Hawaiian or Pacific Islander |
0 |
0 |
0 |
0 |
White |
1 |
5 |
0 |
0 |
Two or More Races or Ethnicities |
0 |
0 |
0 |
0 |
LGBTQ+ |
0 |
Did Not Disclose Demographic Background |
0 |
Director Independence
We believe that the Company benefits from having a strong and independent
Board. For a director to be considered independent, the Board must determine that the director does not have any direct or indirect material
relationship with the Company that would affect his or her exercise of independent judgment. On an annual basis, the Board reviews the
independence of all directors under the applicable Securities and Exchange Commission (the “SEC”) rules and Nasdaq
listing standards. The Board also considers each director’s affiliations with the Company and members of management, as well as
significant holdings of Company securities. This review considers all known relevant facts and circumstances in making an independence
determination. Based on this review, the Board has made an affirmative determination that all directors are independent, other
than our President and Chief Executive Officer and Chair of the Board, Mr. Bitterman.
In addition, Nasdaq listing standards require that, subject to specified
exceptions, each member of our Audit, Compensation, Governance and Nominating Committees of the Board be independent and that members
of our Audit Committee of the Board (the “Audit Committee”) also satisfy independence criteria set forth in Rule 10A-3
under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). The Board has determined that all members
of the Audit Committee, Compensation Committee, Governance Committee, and Nominating Committee are independent under the applicable Nasdaq
listing standards and the Exchange Act.
Board Leadership Structure
The Board believes that it is important to retain the flexibility to
combine or separate the responsibilities of the offices of Chair of the Board and Chief Executive
Officer, as from time to time it may be in our best interests to either combine or separate the roles, and as such does not have a strict
policy regarding the separation of the offices of Chair of the Board and Chief Executive
Officer. In September 2022, the Board appointed our Chair of the Board, Mr. Bitterman, to
the position of Interim Executive Chair of the Board and, in February 2023, appointed Mr.
Bitterman to the position of President and Chief Executive Officer. All other Board members are independent. Upon Mr. Bitterman’s
appointment to the position of Interim Executive Chair of the Board, the Board concurrently
appointed Mr. Ferrara as Lead Independent Director. The Board has determined that selecting our Chief Executive Officer to serve as Chair
of the Board is the most effective leadership model for the Company at this time. Having one individual serve in both roles provides for
clear leadership, accountability, and alignment on corporate strategy. Given the importance of the Company’s clinical programs to
its strategy, the Board believes that Mr. Bitterman is best positioned with in-depth knowledge to provide the Board with the information
and leadership needed for strategic planning for the Company. The Board believes that appointing a Lead Independent Director strengthens
Board governance, as our Lead Independent Director serves as the principal liaison between the Chair
and the independent directors. Our Lead Independent Director also presides at all meetings of the Board at which the Chair is not in attendance,
including the executive sessions of independent directors.
At executive sessions of our independent directors, these directors
speak candidly on any matter of interest. The independent directors meet separately in executive session on at least an annual basis to
discuss matters relating to the Company and the Board, without members of the management team present. We believe this structure provides
consistent and effective oversight of our management and the Company at this time. The Board met in executive session four times in 2022.
Role in Risk Oversight
The Board has overall responsibility for the oversight of the Company’s
risk management process, which is designed to support the achievement of organizational objectives, including strategic objectives, to
improve long-term organizational performance and enhance stockholder value. Risk management includes not only understanding company-specific
risks and the steps management implements to manage those risks, but also what level of risk is acceptable and appropriate for the Company.
Management is responsible for establishing our business strategy, identifying and assessing the related risks and implementing appropriate
risk management practices. The Board periodically reviews our business strategy and management’s assessment of the related risk,
and discusses with management the appropriate level of risk for the Company. The Board also delegates oversight to Board committees to
oversee selected elements of risk.
Related Party Transactions
The Board, with the assistance of the Audit Committee, reviews and
approves all transactions with directors, officers and holders of more than 5% of our voting securities and their affiliates. Prior to
the Board’s consideration of a transaction with such a related party, the material facts as to the related party’s relationship
or interest in the transaction must be disclosed to the Board, and the transaction will not be considered approved by the Board unless
a majority of the directors who are not interested in the transaction (if applicable) approve the transaction. Furthermore, when stockholders
are entitled to vote on a transaction with a related party, the material facts of the related party’s relationship or interest in
the transaction must be disclosed to the stockholders, who must approve the transaction in good faith.
During the past two years, there has not been, nor is there currently
proposed, any transaction or series of related transactions to which we were or will be a party in which the amount involved exceeded
or will exceed the lesser of (i) $120,000 and (ii) one percent of the average of Company's total assets at year-end for the last two completed
fiscal years and in which the other parties included or will include any of our directors, executive officers, holders of 5% or more of
our voting securities, or any member of the immediate family of any of the foregoing persons, other than compensation arrangements with
directors and executive officers, which are described where required in “Executive Compensation” and “Director Compensation.”
Indemnification Agreements
We have entered into indemnification agreements with each of our executive
officers and directors. These agreements provide that, subject to limited exceptions and among other things, we will indemnify each of
our executive officers and directors to the fullest extent permitted by law and advance expenses to each indemnitee in connection with
any proceeding in which a right to indemnification is available.
Prohibition Against Pledging or Hedging
Consistent with our Insider Trading Policy, we prohibit our employees,
officers and directors from pledging our Common Stock or other securities and engaging in hedging transactions with respect to our securities.
Our policies specifically prohibit our executive officers and non-employee directors from holding our securities in any margin account
for investment purposes or otherwise using our securities as collateral for a loan. Our policy also prohibits transactions in publicly
traded options of our securities, such as puts, calls, and other derivative securities, and engaging in short sales of our stock and other
similar transactions that could be used to hedge or offset any decrease in the value of our securities.
Delinquent Section 16(a) Reports
Section 16(a) of the Exchange Act requires the Company’s directors,
executive officers and greater-than-10% stockholders to file forms with the SEC to report their ownership of Company securities and any
changes in ownership. We have reviewed all forms filed electronically with the SEC. Based on that review and on written information given
to us by our officers and directors, we believe that all of our directors, officers and greater-than-10% stockholders filed the required
reports on a timely basis under Section 16(a) during 2022, except for director Patricia Bradford, who on September 26, 2022 filed a Form
4 reporting one transaction that was due August 11, 2022.
Stockholder Communications with Directors
Any stockholders who wish to address questions regarding the business
or affairs of the Company directly with the Board, or any individual director, should direct his or her questions in writing to the Chair
of the Board, or any individual director by name, at Phio Pharmaceuticals Corp., 257 Simarano Drive, Suite 101, Marlborough, MA 01752.
Upon receipt of any such communications, the correspondence will be directed to the appropriate person, including individual directors.
BOARD MEETINGS AND COMMITTEES
During fiscal year 2022, the Board met fourteen times. No director
attended fewer than 75% of the aggregate of the meetings of the Board and meetings of the committees of which such person was a member
in our last fiscal year. The Board has four standing committees: an Audit Committee, a Compensation Committee, a Governance Committee,
and a Nominating Committee. All members of the Audit, Compensation, Governance, and Nominating Committees are non-employee directors who
are deemed independent.
The Company does not have a formal policy regarding attendance of directors
at our annual meeting of stockholders. Five of our directors were present, via teleconference, at our 2022 Annual Meeting of Stockholders.
Board Committees
Audit Committee. As of the Record Date, the Audit
Committee was comprised of Mr. Ferrara (Chair), Ms. Bradford and Dr. Freeman. The Audit Committee selects and appoints the Company’s
independent registered public accounting firm, reviews and oversees the process for monitoring auditor independence, discusses and reviews
independent registered public accounting firm reports and management letters, and oversees and evaluates the performance of the independent
registered public accounting firm. The Audit Committee also pre-approves audit, review and non-audit services provided by our independent
registered public accounting firm. The Audit Committee oversees and reviews the integrity of the Company’s accounting and financial
reporting policies, internal control systems and the Company’s interim and annual financial statements. In addition, the Audit Committee
reviews our compliance with legal and regulatory requirements, reviews related party transactions, investigates any matters pertaining
to integrity of management, reviews financial reporting and accounting standards, reviews the adequacy of our internal controls, meets
with officers as necessary, and performs other duties as specified in the Audit Committee Charter. All members of the Audit Committee
satisfy the current independence and experience requirements of Rule 10A-3 of the Exchange Act and the current Nasdaq independence standards,
and the Board has determined that Mr. Ferrara is an “audit committee financial expert,” as the SEC has defined that term in
Item 407 of Regulation S-K. The Audit Committee met four times in fiscal year 2022.
Compensation Committee. As of the Record Date,
the Compensation Committee of the Board (the “Compensation Committee”) was comprised of Ms. Bradford (Chair), Mr. Ferrara
and Dr. Lockshin. The Compensation Committee determines compensation levels for the Company’s executive officers and directors,
oversees administration of the Company’s equity compensation plans and performs other duties regarding compensation for employees
and consultants as the Board may delegate from time to time. Our Chief Executive Officer makes recommendations to the Compensation Committee
regarding the corporate and individual performance goals and objectives relevant to executive compensation and executives’ performance
in light of such goals and objectives and recommends other executives’ compensation levels to the Compensation Committee based on
such evaluations. The Compensation Committee considers these recommendations and then makes an independent decision regarding officer
compensation levels and awards. All members of the Compensation Committee satisfy the current Nasdaq independence standards, and each
member of the Committee qualifies as an “outside director” Rule 16b-3 of the Exchange Act, respectively. The Compensation
Committee met three times in fiscal year 2022.
Governance and Nominating Committee. In 2022, the Board
determined that the Governance and Nominating Committee of the Board (the “Governance and Nominating Committee”) would
be divided into two separate standing committees of the Board – the Governance Committee of the Board (the “Governance
Committee”) and the Nominating Committee. Prior to dividing into two separate standing committees of the Board, the Governance
and Nominating Committee met three times in fiscal year 2022.
Nominating Committee. As of the Record Date, the
Governance Committee is comprised of Ms. Bradford (Chair) and Dr. Lockshin. The Nominating Committee reviews potential director nominees
and recommends nominees to the Board. All members of the Nominating Committee satisfy the current Nasdaq independence standards. The Nominating
Committee did not meet in fiscal year 2022.
Governance Committee. As of the Record Date, the
Governance Committee is comprised of Drs. Lockshin (Chair) and Freeman. The Governance Committee, among other things, oversees the Company’s
corporate governance principles and develops and implements policies and processes regarding corporate governance matters. All members
of the Governance Committee satisfy the current Nasdaq independence standards. The Governance Committee did not meet in fiscal year 2022.
A copy of the Company’s Audit, Compensation, Governance, and
Nominating Committee charters are available on the Company’s website at www.phiopharma.com.
DIRECTOR COMPENSATION
We compensate our non-employee directors for their service as a member
of the Board. Each non-employee director is entitled to receive an annual cash retainer of $35,000. The chairs of the Board and Audit
Committee are entitled to receive an additional annual cash retainer of $15,000 and the chairs of the Compensation, Governance and Nominating
Committees are entitled to receive an additional cash retainer of $7,500. In addition, the Lead Independent Director is entitled to receive
an additional annual cash retainer of $12,500. Each non-employee director is also entitled to receive an annual grant of 1,667 restricted
stock units (“RSUs”), which vest in full on the one-year anniversary of the respective date of grant.
The Compensation Committee and the Board reassess the appropriate levels
of cash and equity compensation for non-employee directors on an annual basis.
Non-employee directors are also reimbursed for their travel and reasonable
out-of-pocket expenses incurred in connection with attending Board and committee meetings and in attending continuing education seminars,
to the extent that attendance is required by the Board or the committee(s) on which that director serves.
The following table shows the compensation to the Company’s non-employee
directors in fiscal year 2022. We compensate our non-employee directors for their service as a member of the Board. Compensation paid
to Robert J. Bitterman, the Company's President, Chief Executive Officer and Chair of the
Board, and Geert Cauwenbergh, Dr. Med. Sc., who served as the Company’s interim Principal Executive Officer and interim Principal
Financial Officer from May 2022 to September 2022, in connection with their service as directors of the Company are set forth in the Summary
Compensation Table below due to Mr. Bitterman and Dr. Cauwenbergh’s status as named executive officers (“NEOs”)
of the Company.
Name | |
Fees Earned or Paid in Cash ($) | | |
Stock Awards ($)(1) | | |
Total ($) | |
Patricia A. Bradford | |
| 27,292 | | |
| 15,000 | | |
| 42,292 | |
H. Paul Dorman(2) | |
| 16,667 | | |
| 8,612 | | |
| 25,279 | |
Robert L. Ferrara | |
| 49,375 | | |
| 8,612 | | |
| 57,987 | |
Jonathan E. Freeman, Ph.D. | |
| 31,250 | | |
| 8,612 | | |
| 39,862 | |
Curtis A. Lockshin, Ph.D. | |
| 38,750 | | |
| 8,612 | | |
| 47,362 | |
(1) |
The amounts shown reflect the grant date fair value of RSUs computed in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation”. |
|
|
(2) |
Mr. Dorman did not stand for reelection at the 2022 Annual Stockholder Meeting held on August 9, 2022 and served as a director until the end of his term. |
As of December 31, 2022, the aggregate number of shares underlying
stock options and RSUs by our non-employee directors is as follows: Patricia A. Bradford — 1,667 RSUs, Robert L. Ferrara —
834 RSUs, Jonathan E. Freeman, Ph.D. — 1 option award and 834 RSUs, and Curtis A. Lockshin, Ph.D. — 5 option awards and 834
RSUs. Mr. Bitterman and Dr. Cauwenbergh’s outstanding equity awards are also included in the Outstanding Equity Awards at Fiscal
Year-End table below due to their status as NEOs during the fiscal year ended December 31, 2022.
Upon his appointment to President and Chief Executive Officer of the
Company effective February 20, 2023, Mr. Bitterman ceased receiving compensation in connection with his positions as a director of the
Company, including as Chair of the Board.
EXECUTIVE COMPENSATION
Compensation of Named Executive Officers
Our NEOs with respect to the fiscal year that ended on December 31,
2022 are Robert J. Bitterman, Geert Cauwenbergh, Dr. Med. Sc., our former interim Principal Executive and Financial Officer and Gerrit
Dispersyn, Dr. Med. Sc., our former President and Chief Executive Officer, who are referred to collectively as our “named executive
officers” or NEOs.
Summary Compensation Table
The following table provides information regarding the compensation
earned by our NEOs:
Name and principal position | |
Year | |
Salary ($) | |
Stock awards ($)(1) | |
Non-equity incentive plan compensation ($)(2) | |
All other compensation ($)(3) | |
Total ($) | |
Robert J. Bitterman (4) | |
2022 | |
77,885 | |
31,464 | |
– | |
31 | |
109,380 | |
President and Chief Executive Officer | |
2021 | |
47,500 | |
30,800 | |
– | |
– | |
78,300 | |
Geert Cauwenbergh, Dr. Med. Sc.(5) | |
2022 | |
68,750 | |
8,612 | |
– | |
– | |
77,362 | |
Former interim Principal Executive and Financial Officer | |
2021 | |
27,500 | |
30,800 | |
– | |
– | |
58,300 | |
Gerrit Dispersyn, Dr. Med. Sc.(6) | |
2022 | |
178,514 | |
108,511 | |
– | |
202,744 | |
489,769 | |
Former President and Chief Executive Officer | |
2021 | |
403,390 | |
210,826 | |
136,688 | |
575 | |
751,479 | |
(1) |
The amounts shown reflect the grant date fair value of RSUs computed in accordance with the FASB ASC Topic 718, “Compensation — Stock Compensation” for the indicated year. |
(2) |
The amounts shown reflect the annual cash bonus earned for performance for each respective year
under the Company’s Incentive Bonus Program. The annual cash bonus is typically paid in March of the subsequent year. No
annual cash bonuses were paid to our NEOs for 2022. |
(3) |
Represents amounts for the dollar value of life insurance premiums paid, except as noted in footnote 6 below. |
(4) |
Mr. Bitterman has served as a member of the Board since 2012, served as the Company’s Interim Executive Chair from September 2022 to February 2023 and was appointed as our President and Chief Executive Officer in February 2023. The amounts listed in fiscal year 2021 reflect the compensation paid to Mr. Bitterman as a member of the Board. The amounts listed in fiscal year 2022 reflect the compensation paid to Mr. Bitterman as a member of the Board, totaling $46,112, and as our Interim Executive Chair, totaling $63,268. |
(5) |
Dr. Cauwenbergh has served as a member of the Company’s Board since 2012 and served as the Company’s interim Principal Executive and Financial Officer from May 2022 to September 2022. Dr. Cauwenbergh was paid $37,500 in compensation in fiscal year 2022 as the Company’s interim Principal Executive and Financial Officer, which is included within the “Salary” heading of the Summary Compensation Table. All other compensation listed in the Summary Compensation Table reflects the compensation paid to Dr. Cauwenbergh as a member of the Board. |
(6) |
Dr. Dispersyn served as the Company’s President and Chief Executive Officer from March 2019 to May 2022. Included within the “All Other Compensation” heading of the Summary Compensation Table is $202,500 in severance payments made to Dr. Dispersyn in connection with his termination consistent with and subject to the conditions set forth in his employment agreement. |
Outstanding Equity Awards at Fiscal Year-End
The following table shows information regarding outstanding equity
awards as of December 31, 2022 for our NEOs:
| |
| |
Option Awards | |
Stock Awards | |
Name | |
Grant Date | |
Number
of Securities Underlying Unexercised Options (#)
Exercisable | |
Number
of Securities Underlying Unexercised Options (#)
Unexercisable | |
Option
Exercise Price ($) | |
Option Expiration Date | |
Number
of Shares or Units of Stock That Have Not Vested (#) | |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(1) | |
Equity
Incentive Plan Awards: Number of Unearned Shares or Units of
Stock That Have Not Vested (#) | |
Equity Incentive Plan Awards:
Market Value of Unearned Shares or Units of Stock That Have Not Vested ($) | |
Robert J. Bitterman (2) | |
6/7/2013 | |
1 | |
– | |
396,000.00 | |
6/7/2023 | |
– | |
– | |
– | |
– | |
| |
6/2/2014 | |
1 | |
– | |
188,100.00 | |
6/2/2024 | |
– | |
– | |
– | |
– | |
| |
6/1/2015 | |
1 | |
– | |
25,080.00 | |
6/1/2025 | |
– | |
– | |
– | |
– | |
| |
2/10/2016 | |
1 | |
– | |
18,876.00 | |
2/10/2026 | |
– | |
– | |
– | |
– | |
| |
2/1/2017 | |
1 | |
– | |
4,151.40 | |
2/1/2027 | |
– | |
– | |
– | |
– | |
| |
2/15/2022 | |
– | |
– | |
– | |
– | |
834 | |
3,720 | |
– | |
– | |
| |
10/1/2022 | |
– | |
– | |
– | |
– | |
3,334 | |
14,870 | |
– | |
– | |
Geert Cauwenbergh, Dr. Med. Sc. (3) | |
6/7/2013 | |
3 | |
– | |
396,000.00 | |
6/7/2013 | |
– | |
– | |
– | |
– | |
| |
6/2/2014 | |
3 | |
– | |
188,100.00 | |
6/2/2014 | |
– | |
– | |
– | |
– | |
| |
6/1/2015 | |
3 | |
– | |
25,080.00 | |
6/1/2025 | |
– | |
– | |
– | |
– | |
| |
2/10/2016 | |
3 | |
– | |
18,876.00 | |
2/10/2026 | |
– | |
– | |
– | |
– | |
| |
2/1/2017 | |
2 | |
– | |
4,151.40 | |
2/1/2027 | |
– | |
– | |
– | |
– | |
| |
8/1/2018 | |
32 | |
– | |
1,181.40 | |
8/1/2028 | |
– | |
– | |
– | |
– | |
| |
2/15/2022 | |
– | |
– | |
– | |
– | |
834 | |
3,720 | |
– | |
– | |
Gerrit Dispersyn, Dr. Med. Sc. | |
– | |
– | |
– | |
– | |
– | |
– | |
– | |
– | |
– | |
(1) |
Value is based on the closing price of $4.46 of the Company’s Common Stock on December 31, 2022. |
(2) |
The equity awards granted to Mr. Bitterman vest in one installment on the first anniversary of the grant date. |
(3) |
The equity awards granted to Dr. Cauwenbergh from 2013 and 2018 vested over four years commencing on the first anniversary of the grant date. The equity award granted to Dr. Cauwenbergh in 2022 vests in one installment on the first anniversary of the grant date. |
Base Salary
When reviewing and approving our executive
compensation arrangements, including the base salaries paid to our executive officers, the Compensation Committee considers a number of
factors, including, but not limited to: the performance of the executive officer to the Company’s overall performance, the performance
of the executive officer against the Company’s corporate objectives, the executive officer’s skills, experience and qualifications
in such executive officer’s role, review of compensation surveys of base salaries paid by comparable organizations and market compensation
data. These factors provide the framework for decisions regarding the base salary compensation for each executive officer. No single factor
is determinative in setting base salary levels, nor was the impact of any factor on the determination of pay levels quantifiable.
Incentive Compensation
Annual Incentive Bonus
Annual bonuses are based on the achievement
of corporate goals typically comprised of a mix of clinical development, discovery, financial, business development, and investor relations
related performance objectives. The corporate goals are approved by the Board on an annual basis at the start of each year. Annual bonuses
for all employees, including executive officers, take into account the achievement of specified business objectives and individual performance
objectives, with the exception of the Company's President and Chief Executive Officer, whose annual bonus is determined solely by the
achievement of business objectives. The Compensation Committee reviews our achievements against these corporate goals and their assessment
of the goals and recommendations regarding achievement is presented to our full Board for approval. The Compensation Committee maintains
full discretion in determining overall performance under the annual bonus and may adjust bonus payouts based on factors it deems relevant.
Annual incentive bonus payouts to our NEOs are disclosed in the Summary Compensation Table above.
Equity Incentive
We maintain our 2020 Long Term Incentive Plan
(“2020 Plan”) pursuant to which we currently grant RSU awards to eligible participants. Grants of RSUs under this plan
to our NEOs are disclosed in the Summary Compensation Table and Outstanding Equity Awards at Fiscal Year-End table above.
Employment and Change of Control Agreements
The following provides descriptions of the
employment agreements that are currently or were in effect for our NEOs:
Robert J. Bitterman
Mr. Bitterman was appointed President and
Chief Executive Officer and entered into an employment agreement, dated February 20, 2023, pursuant to which he will be entitled to an
initial annual base salary of $440,000 and will be eligible to receive an annual bonus of up to 40% of his annual base salary, based on
the achievement of certain performance goals established annually by the Board. In connection with his appointment, the Company granted
Mr. Bitterman RSUs settleable for 11,000 shares of the Company's Common Stock under the Company's 2020 Plan. The RSUs will vest in two
equal annual installments, commencing on the first anniversary of the date of grant, subject to Mr. Bitterman’s continuous service
with the Company through each such vesting date.
If Mr. Bitterman’s employment is terminated
by the Company due to death or disability, the Company shall pay to Mr. Bitterman or to his estate, as applicable, any earned, but unpaid,
base salary and any amounts owed to Mr. Bitterman for reimbursement of expenses properly incurred which are reimbursable, in each case
as earned or incurred, as applicable through the date of termination (the “Accrued Benefits”), as well as pay any accrued
but unpaid bonus then due to Mr. Bitterman and all equity awards that have been granted will immediately vest on a pro-rata basis. If
Mr. Bitterman’s employment is terminated by the Board for cause or by Mr. Bitterman without good reason, the Company shall pay to
Mr. Bitterman the Accrued Benefits through the date of termination. If Mr. Bitterman’s employment is terminated by Mr. Bitterman
for good reason or by the Company other than as a result of death or disability and other than for cause, then the Company shall pay to
Mr. Bitterman the Accrued Benefits through the date of termination, continue to pay Mr. Bitterman his base salary for three months from
the date of separation, pay any accrued but unpaid bonus and if, and only if, such termination occurs within one year of a change in control
all equity awards that have been granted but are not exercisable at the time of such termination shall immediately become exercisable
in full.
Mr. Bitterman is eligible to participate in
the Company’s 2020 Plan and other benefits available to the Company’s executive officers.
Geert Cauwenbergh, Dr. Med. Sc.
In connection with his employment as the Company’s
interim Principal Executive Officer and Principal Financial Officer, Dr. Cauwenbergh received a monthly cash payment of $7,500.
Gerrit Dispersyn, Dr. Med. Sc.
We entered into an employment agreement with
Dr. Dispersyn effective April 24, 2017 as our Chief Development Officer. As Chief Development Officer, Dr. Dispersyn was entitled to receive
an initial base salary of $285,000 per annum, as well as a performance bonus of up to 30% of his base salary, subject to the achievement
of performance goals to be established annually. In connection with Dr. Dispersyn’s appointment to Chief Development Officer, he
received a stock option entitling him to purchase 14 shares of the Company’s Common Stock, which were subject to vesting in equal
monthly installments over four years following the date of grant.
Dr. Dispersyn served as the Company’s
President and Chief Executive Officer from March 2019 to May 2022. As President and Chief Executive Officer, Dr. Dispersyn was entitled
to an initial base salary of $380,000 per annum, as well as a performance bonus of up to 50% of his base salary, subject to the achievement
of performance goals to be established annually. As a one-time award in connection with his appointment on March 1, 2019, Dr. Dispersyn
received RSUs settleable for 617 shares of the Company’s Common Stock, which was subject to vesting in equal annual installments
over four years.
Dr. Dispersyn’s employment agreement
provided that, upon termination of Dr. Dispersyn’s employment without cause by us, he would be entitled to payment of: (1) any accrued
but unpaid salary and unused vacation as of the date of his termination; (2) six months of salary from the date of termination; and (3)
continued participation, at our expense, during the applicable six-month severance period in our sponsored group medical and dental plans.
Effective May 5, 2022, Dr. Dispersyn’s employment with the Company ended, which was treated as a termination without “cause,”
and Dr. Dispersyn became entitled to receive severance benefits totaling $202,500 consistent with the above and subject to the conditions
set forth in the separation agreement between Dr. Dispersyn and the Company.
Pay for Performance Analysis
As required by Section 953(a) of the Dodd-Frank
Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about the
relationship between the SEC-defined Compensation Actually Paid (“CAP”) to our NEOs and certain of our financial performance
metrics during the fiscal years listed below. The SEC-defined CAP data set forth in the table below does not necessarily reflect amounts
actually paid, earned or received by our NEOs, and the metrics are not those that the Compensation Committee uses when setting executive
compensation.
The following table sets forth additional compensation
information of our principal executive officers (“PEOs”) along with total shareholder return and net income for our
2022 and 2021 fiscal years. The Company did not have any non-PEO NEOs for fiscal years 2022 and 2021.
Year |
Summary Compensation Table Total for
PEO #1
(1) |
Compensation Actually Paid to
PEO #1
(4) |
Summary Compensation Table Total for PEO #2
(2) |
Compensation Actually Paid to PEO #2
(4) |
Summary Compensation Table Total for PEO #3
(3) |
Compensation Actually Paid to
PEO #3
(4) |
Value of Initial Fixed $100 Investment
Based On Total Shareholder Return
(5) |
Net Income (Loss)
(Thousands) |
2022 |
109,380 |
94,715 |
77,362 |
70,562 |
489,769 |
304,074 |
$13.83 |
(11,480) |
2021 |
78,300 |
57,508 |
58,300 |
36,702 |
751,479 |
594,235 |
$37.17 |
(13,287) |
| (1) | Mr. Bitterman (PEO #1) has served as a member of the Company’s Board since 2012, served as the Company’s Interim Executive
Chair from September 2022 to February 2023 and was appointed as our President and Chief Executive
Officer in February 2023. |
| (2) | Dr. Cauwenbergh (PEO #2) has served as a member of the Company’s Board since 2012 and served as the Company’s interim
Principal Executive and Financial Officer from May 2022 to September 2022. |
| (3) | Dr. Dispersyn (PEO #3) served as the Company’s President and Chief Executive Officer from March 2019 to May 2022. |
| (4) | Compensation Actually Paid reflects the following exclusions and inclusions for each of the PEOs in the table above: |
PEO #1
Year |
Summary Compensation Table Total |
Minus: Grant Date Fair Value of Stock Awards and Option Awards from Summary Compensation Table |
Plus: Year-end Fair Value of Unvested Equity Awards Granted During Year |
Plus: Year-Over-Year Difference
of Year-End Fair Value of
Unvested
Awards
Granted in
Prior Years |
Plus: Fair Value at Vest Date for Awards Granted and Vested During Year |
Plus:
Year-Over-Year Difference of Year-End Fair Value of Prior Years’ Awards Vested During Year |
Minus: Fair Value at Prior Year-end for Prior Years’ Awards that Fail to Meet Vesting Conditions During Year |
Compensation Actually Paid |
2022 |
109,380 |
(31,464) |
18,590 |
– |
– |
(1,791) |
– |
94,715 |
2021 |
78,300 |
(30,800) |
10,008 |
– |
– |
– |
– |
57,508 |
PEO #2
Year |
Summary Compensation Table Total |
Minus: Grant Date Fair Value of Stock Awards and Option Awards from Summary Compensation Table |
Plus: Year-end Fair Value of Unvested Equity Awards Granted During Year |
Plus: Year-Over-Year Difference
of Year-End Fair Value of
Unvested
Awards
Granted in
Prior Years |
Plus: Fair Value at Vest Date for Awards Granted and Vested During Year |
Plus:
Year-Over-Year Difference of Year-End Fair Value of Prior Years’ Awards Vested During Year |
Minus: Fair Value at Prior Year-end for Prior Years’ Awards that Fail to Meet Vesting Conditions During Year |
Compensation Actually Paid |
2022 |
77,362 |
(8,612) |
3,720 |
– |
– |
(1,908) |
– |
70,562 |
2021 |
58,300 |
(30,800) |
10,008 |
(806) |
– |
– |
– |
36,702 |
PEO #3
Year |
Summary Compensation Table Total |
Minus: Grant Date Fair Value of Stock Awards and Option Awards from Summary Compensation Table |
Plus: Year-end Fair Value of Unvested Equity Awards Granted During Year |
Plus: Year-Over-Year Difference
of Year-End Fair Value of
Unvested
Awards
Granted in
Prior Years |
Plus: Fair Value at Vest Date for Awards Granted and Vested During Year |
Plus:
Year-Over-Year Difference of Year-End Fair Value of Prior Years’ Awards Vested During Year |
Minus: Fair Value at Prior Year-end for Prior Years’ Awards that Fail to Meet Vesting Conditions During Year |
Compensation Actually Paid |
2022 |
489,769 |
(108,511) |
– |
– |
– |
– |
(77,184) |
304,074 |
2021 |
751,479 |
(210,826) |
68,460 |
(14,870) |
– |
(8) |
– |
594,235 |
| (5) | Total shareholder return as calculated based on a fixed investment of $100 measured from the market close on December 31, 2020 through
and including the end of the fiscal year for each year reported in the table. |
Relationship Between Pay and Performance
The following charts shown below illustrate the relationship of compensation
actually paid to our PEOs, as set forth in the table above, as compared to: our (1) total shareholder return and (2) net income (loss).
PROPOSAL NO. 2
RATIFICATION OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
Our Audit Committee has selected BDO USA, LLP (“BDO”)
as our independent registered public accounting firm for the fiscal year ending December 31, 2023, and has further directed that we submit
the selection of BDO for ratification by our stockholders at the Annual Meeting.
The Company is not required to submit the selection of our independent
registered public accounting firm for stockholder approval. However, if the stockholders do not ratify this selection, the Audit Committee
will reconsider its selection of BDO. Even if the selection is ratified, our Audit Committee may appoint a different independent registered
public accounting firm at any time during the year if the Audit Committee determines that the change would be in the best interests of
the Company.
Under the Sarbanes-Oxley Act of 2002, all audit and permissible non-audit
services provided by our independent registered public accounting firm must be approved in advance by our Audit Committee to ensure that
such services do not impair the independent registered public accounting firm’s independence from us. Accordingly, the Audit Committee
reviews and pre-approves all audit and non-audit services performed by its independent registered public accounting firm, as well as the
fees charged for such services. In its review of non-audit service fees, the Audit Committee considers, among other things, the possible
impact of the performance of such services on the independent registered public accounting firm’s independence. All fees incurred
in fiscal years 2022 and 2021 for services rendered by BDO were approved in accordance with these policies. Additional information concerning
the Audit Committee and its activities can be found in the “Board Committees” section of this Proxy Statement.
Representatives of BDO are expected to be present at the Annual Meeting,
will have the opportunity to make a statement if they desire to do so and will be available to respond to appropriate stockholder questions.
Fees for Independent Registered Public Accounting Firm
The following is a summary of the fees billed and expected to be billed
to the Company by BDO for professional services rendered for the fiscal years ended December 31, 2022 and 2021.
| |
2022 | | |
2021 | |
Audit Fees | |
$ | 215,974 | | |
$ | 187,352 | |
Audit-Related Fees | |
| – | | |
| – | |
Tax Fees | |
| – | | |
| 36,250 | |
All Other Fees | |
| – | | |
| – | |
Total All Fees: | |
$ | 215,974 | | |
$ | 223,602 | |
Audit Fees consist of fees for the audit of the Company’s
financial statements included in our annual reports on Form 10-K, the review of the Company’s financial statements included in our
quarterly reports on Form 10-Q and other statutory and regulatory filings, including auditor consents.
Audit-Related Fees consist of fees billed for assurance and
related services that are also performed by our independent registered public accounting firm.
Tax Fees consist of services rendered for tax compliance, tax
advice and tax planning.
All Other Fees consist
of the aggregate fees billed for products and services provided by BDO and not otherwise included in Audit Fees, Audit-Related Fees or
Tax Fees.
REPORT OF THE AUDIT COMMITTEE
The Audit Committee operates under a written Audit Committee charter
that has been adopted by the Board in managing relations with the Company’s independent registered public accounting firm and evaluating
auditor performance. The Audit Committee functions are not intended to duplicate or to certify the activities of management. The Audit
Committee serves as a Board-level oversight role in which it provides advice, counsel and direction to management and the auditors on
the basis of the information it receives, discussions with management and the auditors, and the experience of the Audit Committee’s
members in business, financial and accounting matters. All members of the Audit Committee currently meet the independence and qualification
standards for Audit Committee membership set forth in the listing standards provided by Nasdaq and the SEC.
The Audit Committee oversees the Company’s financial reporting
process on behalf of the Board. The Company’s management has the primary responsibility for the financial statements and reporting
process, including the Company’s system of internal controls. The Company’s independent registered public accounting firm
is responsible for performing an independent audit of the Company’s consolidated financial statements in accordance with accounting
principles generally accepted auditing standards and for issuing a report thereon.
In fulfilling its oversight responsibilities, the Audit Committee reviewed
and discussed with management the audited financial statements and disclosures included in the Annual Report on Form 10-K for the fiscal
year ended December 31, 2022. The Audit Committee also reviewed with the Company’s independent registered public accounting firm
their judgments as to the quality and the acceptability of the Company’s financial reporting and such other matters as are required
to be discussed with the Committee under applicable requirements of the Public Company Accounting Oversight Board (the “PCAOB”)
and the SEC.
The Audit Committee received the written disclosures and the letter
from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent registered
public accounting firm’s communications with the Audit Committee concerning independence and the Audit Committee discussed with
the independent registered public accounting firm their independence from the Company, including the matters required by the applicable
rules of the PCAOB.
Based on the reviews and discussions referred to above, the Audit Committee
recommended to the Board that the Company’s audited financial statements should be included in the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2022.
Robert L. Ferrara
Patricia A. Bradford
Jonathan E. Freeman, Ph.D.
Recommendation
The Board recommends a vote “FOR” the ratification of BDO
as our independent registered public accounting firm for the fiscal year ending December 31, 2023. Proxies will be so voted unless stockholders
specify otherwise in their proxies.
Vote Required
Ratification of the selection of the independent registered public
accounting firm requires the affirmative vote of a majority of the votes cast on the matter. Abstentions and broker non-votes (if any)
will be entirely excluded from the vote and will have no effect on its outcome.
THE BOARD RECOMMENDS A VOTE “FOR”
PROPOSAL NO. 2.
PROPOSAL NO. 3
APPROVAL OF AN AMENDMENT AND
RESTATEMENT OF THE 2020 PHIO PHARMACEUTICALS CORP.
LONG TERM INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE THEREUNDER BY 125,500
The Board believes that RSUs and other stock-based incentive awards
can play an important role in the success of the Company. These incentives are given to employees, officers, directors and other key persons
of the Company and provide these individuals with a proprietary interest in the Company. The Board believes
a compensation policy that includes a balanced mix of cash and equity is the most effective way to attract and retain talented employees
whose interests are aligned with stockholders.
Background
The purpose of the 2020 Plan is to advance
the interests of the Company by giving stock-based incentives to the employees, officers, directors and other key persons
of the Company who are in a position to make a significant contribution to the success of the Company. The 2020 Plan was originally adopted
by the Board in August 2020 and by our stockholders in October 2020 as a successor to the 2012 Phio Pharmaceuticals Corp. Long Term Incentive
Plan (the “2012 Plan”), which expired on January 23, 2022. Upon adoption of the 2020 Plan, no further awards were made
under the 2012 Plan and shares that remained available for grant and that were subject to outstanding awards under the 2012 Plan were
included in the authorized shares available for grant under the 2020 Plan.
As of April 30, 2023, there were 72,932 shares of Common Stock
subject to outstanding RSUs and options and 243 shares of Common Stock that remained available for issuance under the 2020 Plan. In
order to continue to provide employees, officers, directors and other key persons with stock-based incentives, the Board has
authorized an amendment and restatement of the 2020 Plan, subject to stockholder approval.
The amendment and restatement will increase the number
of shares of Common Stock reserved for issuance under the 2020 Plan by 125,500 shares to a total of 225,500 shares, which represents approximately
15% of the total outstanding shares of our Common Stock as of April 30, 2023. The Board currently intends that the additional 125,500
shares under the 2020 Plan will be sufficient to fund the Company’s equity compensation needs for approximately 1 - 2 years. There
are no other proposed changes to the 2020 Plan.
While approving the share increase under the 2020 Plan,
the Board considered, among other things, the following:
|
· |
Potential dilution to its current stockholders as measured by burn rate and overhang (as described in “Key Data” below); |
|
|
|
|
· |
The recommendations of stockholder advisory firms like Institutional Shareholder Services and Glass Lewis; |
|
|
|
|
· |
Market standards and peer group companies; |
|
|
|
|
· |
100% employee participation in the 2020 Plan; and |
|
|
|
|
· |
The continued importance of motivating, recruiting and retaining key employees. |
Key Data
When approving the share increase under the 2020 Plan, the
Board considered the burn rate with respect to the equity awards granted by the Company, as well as the Company’s overhang. The
burn rate is equal to the total number of equity awards the Company granted in a fiscal year divided by the weighted average Common Stock
outstanding during the year. The Company’s three-year average burn rate at the time the Board approved the share increase under
the 2020 Plan was approximately 3%.
Overhang is equal to the total number of equity awards outstanding
plus the total number of shares available for grant under the Company’s equity plans, divided by the sum of the total Common Stock
outstanding, the number of equity awards outstanding and the total number of shares available for grant under the Company’s equity
plans. The Company’s overhang as of April 30, 2023 was 5%. If the share increase under the 2020 Plan is approved, the Company’s
overhang would increase to 12%.
The following table sets forth information regarding
outstanding equity awards and shares available for future equity awards under the 2020 Plan as of April 30, 2023 (without giving effect
to approval of the share increase under the 2020 Plan):
Total shares underlying outstanding stock options | |
| 177 | |
Weighted average exercise price of outstanding stock options | |
$ | 35,231.40 | |
Weighted average remaining contractual life of outstanding stock options (in years) | |
| 3.80 | |
Total shares underlying outstanding unvested RSUs | |
| 72,755 | |
Total shares remaining available for issuance | |
| 243 | |
Total shares of Common Stock outstanding as of April 30, 2023 | |
| 1,504,565 | |
Promotion of Good Corporate Governance Practices
The 2020 Plan provides for the following governance features:
| · | Awards subject to exercise, including stock options and stock appreciation rights, may not have a term in excess of ten years and
may not be granted at a discount to the fair market value of our Common Stock on the grant date; |
| · | Award may not be repriced without stockholder approval; |
| · | Awards under the 2020 Plan, including any shares subject to an award, may be subject to any recovery, recoupment, claw back and/or
other forfeiture policy maintained by the Company now or in the future; |
| · | Awards will be subject to a minimum vesting period of one year after the grant date with respect to 95% of the shares reserved for
issuance under the 2020 Plan. This minimum vesting requirement will not apply to the other 5% of the share pool. Exceptions to this minimum
vesting provision will apply in the case of awards that accelerate and vest on a change of control, death or disability or awards made
to non-employee directors that vest at the next annual shareholder meeting, provided that annual meetings are at least 50 weeks apart.
Such awards will not count against the 5% share pool reserve or be subject to the minimum vesting requirement; |
| · | The 2020 Plan includes a $500,000 cap on the aggregate dollar value of equity-based (based on grant date fair value) and cash compensation
granted under the plan or otherwise during any calendar year to any non-employee director, which limit is increased by 200% in the calendar
year in which the non-employee director first joins the Board or is designated as Chair of
the Board; and |
| · | Dividend and dividend equivalent rights may not be paid on any unvested restricted stock or RSUs or unearned performance awards. |
Summary of the 2020 Plan
as Amended
The following summary of the material terms of the 2020
Plan is qualified in its entirety by reference to the complete text of the 2020 Plan which is set forth in Appendix A to this Proxy Statement,
as amended by this Proposal 3. Stockholders are encouraged to read the text of the 2020 Plan in its entirety. All references below to
the 2020 Plan are references to the amended and restated version of the 2020 Plan unless the context requires otherwise.
Purpose. The 2020 Plan is intended to help us
secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for our success
and provide a means by which the eligible recipients may benefit from increases in the value of our Common Stock.
Eligibility. Awards
may be granted to our and our subsidiaries’ employees, including officers, non-employee directors and consultants. Only our employees
and those of our subsidiaries are eligible to receive incentive stock options. As of April 30, 2023, 10 employees and 5 non-employee directors
would have been eligible to receive awards under the 2020 Plan.
Types of Awards. The
2020 Plan provides for the grant of incentive stock options within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986
(the “Code”), non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance
stock awards and performance cash awards.
Authorized Shares. Subject
to adjustment for certain dilutive or related events, the aggregate maximum number of shares of our Common Stock that may be issued pursuant
to stock awards under the 2020 Plan is 225,500 shares of Common Stock plus (A) any shares of Common Stock that remain available for grant
under the 2012 Plan as of the Effective Date and (B) any shares of Common Stock subject to outstanding awards under the 2012 Plan as of
the Effective Date that on or after the Effective Date are forfeited, terminated, expire or otherwise lapse without being exercised (to
the extent applicable), or are settled in cash.
If a stock award or any portion of a stock
award expires, is cancelled or forfeited or otherwise terminates without all of the shares covered by the stock award having been issued,
then the shares of Common subject to the stock award (or portion thereof) that expires, is cancelled or forfeited or otherwise terminates
shall revert and again be available for issuance under the 2020 Plan. If any shares of Common Stock are repurchased by the Company using
proceeds from the exercise or purchase price of a stock award, or retained because the stock award (or a portion thereof) is settled in
cash (i.e., the participant receives cash rather than stock), then the shares that are repurchased or retained shall not revert and will
not become available for issuance under the 2020 Plan. Any shares retained and not issued by the Company in satisfaction of tax withholding
obligations on a stock award or as consideration for the exercise or purchase price of a stock award will reduce the number of shares
of Common Stock that are available for issuance under the 2020 Plan and such shares shall not be available for issuance under the 2020
Plan.
The aggregate maximum number of shares
of Common Stock that may be issued on the exercise of incentive stock options is 225,500. Shares issued under the 2020 Plan may consist
of our authorized but unissued or reacquired Common Stock, including shares repurchased by us on the open market or otherwise or shares
classified as treasury shares.
The 2020 Plan includes a $500,000 cap on the aggregate
dollar value of equity-based (based on grant date fair value) and cash compensation granted under the plan or otherwise during any calendar
year to any non-employee director, which limit is increased by 200% in the calendar year in which the non-employee director first joins
the Board or is designated as Chair of the Board.
Plan Administration. The Board
has the authority to administer the 2020 Plan, including the powers to: (i) determine who will be granted awards and what type of award,
when and how each award will be granted, the provisions of each award (which need not be identical), the number of shares or cash value
subject to an award and the fair market value applicable to an award; (ii) construe and interpret the 2020 Plan and awards granted thereunder
and establish, amend and revoke rules and regulations for administration of the 2020 Plan and awards, including the ability to correct
any defect, omission or inconsistency in the 2020 Plan or any award document; (iii) settle all controversies regarding the 2020 Plan and
awards granted thereunder; (iv) accelerate or extend, in whole or in part, the time during which an award may be exercised or vested or
at which cash or shares may be issued; (v) suspend or terminate the 2020 Plan; (vi) amend the 2020 Plan; (vii) submit any amendment to
the 2020 Plan for stockholder approval; (viii) approve forms of award documents for use under the 2020 Plan and to amend the terms of
any one or more outstanding awards; (ix) generally exercise such powers and perform such acts as the Board may deem necessary or expedient
to promote our best interests and that are not in conflict with the provisions of the 2020 Plan or any award documents; and (x) adopt
procedures and sub-plans as are necessary or appropriate.
Subject to the provisions
of the 2020 Plan, the Board may delegate all or some of the administration of the 2020 Plan to a committee
of one or more directors and may delegate to one or more officers the authority to designate employees who are not officers to be recipients
of options and stock appreciation rights (and, to the extent permitted by applicable law, other stock awards) and, to the extent permitted
by applicable law, to determine the terms of such awards and the number of shares of Common Stock to be subject to such stock awards granted
to such employees. Unless otherwise provided by the Board, delegation of authority by the Board
to a committee or an officer will not limit the authority of the Board. All determinations, interpretations
and constructions made by the Board (or another authorized committee or officer exercising powers
delegated by the Board) in good faith will be final, binding and conclusive on all persons.
Stock Options. A
stock option may be granted as an incentive stock option (“ISO”) or a nonqualified stock option (“NQSO”).
The option exercise price may not be less than the fair market value of the stock subject to the option on the date the option is granted
or, with respect to incentive stock options, less than 110% of the fair market value if the recipient owns stock possessing more than
10% of the total combined voting power of all classes of our stock or the stock of any affiliate (a “Ten Percent Stockholder”)
unless the option was granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section
409A and, if applicable, Section 424(a) of the Code. Options will not be exercisable after the expiration of ten years from the date of
grant (or five years, in the case of an incentive stock option issued to a Ten Percent Stockholder). Each award agreement will set forth
the number of shares subject to each option. The purchase price of any shares acquired pursuant to an option may be payable in cash, check,
bank draft, money order, net exercise or as otherwise determined by the Board and set forth in the
award agreement, including through an irrevocable commitment by a broker to pay over such amount from a sale of the shares issuable under
the option and the delivery of previously owned shares. The vesting schedule applicable to any option, including any performance conditions,
will be as set forth in the award agreement.
Stock Appreciation Rights. A
stock appreciation right (“SAR”) is a right that entitles the participant to receive, in cash or shares of stock or
a combination thereof, as determined by the Board, value equal to or otherwise based on the excess
of (i) the fair market value of a specified number of shares at the time of exercise over (ii) the exercise price of the right, as established
by the Board on the date of grant. Upon exercising a SAR, the participant is entitled to receive the
amount by which the fair market value of the stock at the time of exercise exceeds the exercise price of the SAR. The exercise price of
each SAR may not be less than the fair market value of the stock subject to the award on the date the SAR is granted, unless the SAR was
granted pursuant to an assumption of or substitution for another option in a manner satisfying the provisions of Section 409A of the Code.
SARs will not be exercisable after the expiration of ten years from the date of grant. Each award agreement will set forth the number
of shares subject to the SAR. The vesting schedule applicable to any SAR, including any performance conditions, will be as set forth in
the award agreement.
Provisions Applicable to Both Options
and SARs.
Transferability. The
Board may, in its sole discretion, impose limitations on the transferability of options and SARs. Unless the Board
provides otherwise, an option or SAR will not be transferable except by will or the laws of descent and distribution and will be exercisable
during the lifetime of a participant only by such participant. The Board may permit transfer of an option or SAR in a manner not prohibited
by applicable law. Subject to approval by the Board, an option or SAR may be transferred pursuant to the terms of a domestic relations
order or similar instrument or pursuant to a beneficiary designation.
Termination of Service. Except
as otherwise provided in an applicable award document or other agreement between us or any affiliate and a participant, upon a termination
for any reason other than for cause or due to death or disability, a participant may exercise his or her option or SAR (to the extent
such award was exercisable as of the date of termination) for a period of three months following the termination date or, if earlier,
until the expiration of the term of such award. Upon a termination due to a participant’s disability, unless otherwise provided
in an applicable award or other agreement, the participant may exercise his or her option or SAR (to the extent that such award was exercisable
as of the date of termination) for a period of 12 months following the termination date or, if earlier, until the expiration of the term
of such award. Upon a termination due to a participant’s death, unless otherwise provided in an applicable award or other agreement,
the participant’s estate may exercise the option or SAR (to the extent such award was exercisable as of the termination date) for
a period of 18 months following the termination date or, if earlier, until the expiration of the term of such award. Unless provided otherwise
in an award or other agreement, an option or SAR will terminate on the date that a participant is terminated for cause and the participant
will not be permitted to exercise such award.
Neither an option nor SAR may be modified
to reduce the exercise price thereof nor may a new option, SAR or other award at a lower price be substituted or exchanged for a surrendered
option or SAR (other than adjustments or substitutions in accordance with the 2020 Plan relating to certain dilutive or related events),
unless such action is approved by the stockholders of the Company.
Awards Other Than Options and SARs.
Restricted Stock and Restricted Stock
Units. Restricted Stock are awards of shares, the grant, issuance, retention, vesting and/or transferability of which is subject
during specified periods of time to such conditions (including continued employment) and terms as the Board deems appropriate. RSUs are
awards denominated in units under which the issuance of shares (or cash payment in lieu thereof) is subject to such conditions (including
continued employment) and terms as the Board deems appropriate. Each award document evidencing a grant of restricted stock or RSUs will
set forth the terms and conditions of each award, including vesting and forfeiture provisions, transferability and, if applicable, right
to receive dividends or dividend equivalents.
Performance Awards. A performance
award is a stock or cash award that is payable contingent upon the attainment during a performance period of certain performance goals.
A performance award may, but need not, require the completion of a specified period of service. The length of any performance period,
the applicable performance goals and the measurement of whether and to what degree such performance goals have been attained will be as
determined by the Compensation Committee, the Board or an authorized officer. The Board, the Compensation Committee or any authorized
officer retains the discretion to define the manner of calculating the performance criteria it selects to use for a performance period.
Certain Adjustments. In the
event of any change in our capitalization, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number
of securities subject to the 2020 Plan; (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise
of incentive stock options; and (iii) the class(es) and number of securities or other property and value (including price per share of
stock) subject to outstanding stock awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.
Unless provided otherwise in an award or other agreement, in the event of our dissolution or liquidation, all outstanding stock awards
(other than stock awards consisting of vested and outstanding shares of our Common Stock not subject to a forfeiture condition or our
right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock
subject to our repurchase rights or subject to forfeiture may be repurchased or reacquired by us notwithstanding the fact that the holder
of such stock award is providing continuous service; provided, however, that the Board may, in its sole discretion, provide that some
or all stock awards will become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent not already
expired or terminated) before the dissolution or liquidation is completed but contingent upon its completion.
Change in Control. Unless provided
otherwise in an award agreement or other agreement between us or an affiliate and the participant, in the event of Change in Control (as
defined in the 2020 Plan), the Board will take one or more of the following actions with respect to each outstanding award, contingent
upon the closing or completion of the Change in Control:
(i) |
arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) to assume or continue the award or to substitute a similar stock award for the award (including, but not limited to, an award to acquire the same consideration per share paid to the stockholders of the company pursuant to the Change in Control); |
(ii) |
arrange for the assignment of any reacquisition or repurchase rights held by us in respect of Common Stock issued pursuant to the award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company); |
(iii) |
accelerate the vesting, in whole or in part, of the award (and, if applicable, the time at which the award may be exercised) to a date prior to the effective time of such Change in Control as determined by the Board, with such award terminating if not exercised (if applicable) at or prior to the effective time of the Change in Control, and with such exercise reversed if the Change in Control does not become effective; |
(iv) |
arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us with respect to the award; |
(v) |
cancel or arrange for the cancellation of the award, to the extent not vested or not exercised prior to the effective time of the Change in Control, in exchange for such cash consideration, if any, as the Board, in its reasonable determination, may consider appropriate as an approximation of the value of the canceled award; and |
(vi) |
cancel or arrange for the cancellation of the award, to the extent not vested or not exercised prior to the effective time of the Change in Control, in exchange for a payment equal to the excess, if any, of (A) the value in the Change in Control of the property the participant would have received upon the exercise of the award immediately prior to the effective time of the Change in Control, over (B) any exercise price payable by such holder in connection with such exercise. |
The Board need not take the same action
or actions with respect to all awards or portions thereof or with respect to all participants and may take different actions with respect
to the vested and unvested portions of an award. In the absence of any affirmative determination by the Board at the time of a Change
in Control, each outstanding award will be assumed or an equivalent award will be substituted by such successor corporation or a parent
or subsidiary of such successor corporation, referred to as a successor corporation, unless the successor corporation does not agree to
assume the award or to substitute an equivalent award, in which case the vesting of such award will accelerate in its entirety (along
with, if applicable, the time at which the award may be exercised) to a date prior to the effective time of such Change in Control as
the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of
the Change in Control), with such award terminating if not exercised (if applicable) at or prior to the effective time of the Change in
Control, and with such exercise reversed if the Change in Control does not become effective.
Acceleration of Awards upon a Change
in Control. An award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as
may be provided in the award agreement for such award or as may be provided in any other written agreement between us or an affiliate
and the participant, but in the absence of such provision, no such acceleration will occur.
Termination and Amendment. The
Board or the Compensation Committee may suspend or terminate the 2020 Plan at any time. No incentive stock options may be granted under
the 2020 Plan after the tenth anniversary of the date on which the Board adopted the 2020 Plan. No awards may be granted under the 2020
Plan while the 2020 Plan is suspended or after it is terminated.
Certain U.S. Federal Income Tax Consequences
The following discussion of the federal income
tax consequences of the 2020 Plan is intended to be a summary of applicable federal law as currently in effect. It should not be taken
as tax advice by participants, who are urged to consult their individual tax advisors.
Stock Options. ISOs and NQSOs are treated differently
for federal income tax purposes. ISOs are intended to comply with the requirements of Section 422 of the Code. NQSOs do not comply with
such requirements. An optionee is not taxed on the grant or exercise of an ISO. The difference between the exercise price and the fair
market value of the shares on the exercise date will, however, be a preference item for purposes of the alternative minimum tax. If an
optionee holds the shares acquired upon exercise of an ISO for at least two years following the option grant date and at least one year
following exercise, the optionee’s gain, if any, upon a subsequent disposition of such shares is a long term capital gain. The measure
of the gain is the difference between the proceeds received on disposition and the optionee’s basis in the shares (which generally
equals the exercise price). If an optionee disposes of stock acquired pursuant to the exercise of an ISO before satisfying these holding
periods, the optionee will recognize both ordinary income and capital gain in the year of disposition. The Company is not entitled to
an income tax deduction on the grant or exercise of an ISO or on the optionee’s disposition of the shares after satisfying the holding
period requirement described above. If the holding periods are not satisfied, the Company will be entitled to a deduction in the year
the optionee disposes of the shares in an amount equal to the ordinary income recognized by the optionee.
In order for an option to qualify for ISO tax treatment, the grant
of the option must satisfy various other conditions more fully described in the Code. The Company does not guarantee that any option will
qualify for ISO tax treatment even if the option is intended to qualify for such treatment. In the event an option intended to be an ISO
fails to qualify, it will be taxed as an NQSO as described below.
An optionee is not taxed on the grant of an NQSO. On exercise, the
optionee recognizes ordinary income equal to the difference between the exercise price and the fair market value of the shares acquired
on the date of exercise. The Company is entitled to an income tax deduction in the year of exercise in the amount recognized by the optionee
as ordinary income. The optionee’s gain (or loss) on a subsequent disposition of the shares is a long term capital gain (or loss)
if the shares are held for at least one year following exercise. The Company does not receive a deduction for this gain.
SARs. An optionee is not taxed on the grant of a SAR. On exercise,
the optionee recognizes ordinary income equal to the cash or the fair market value of any shares received. The Company is entitled to
an income tax deduction in the year of exercise in the amount recognized by the optionee as ordinary income.
Restricted Stock and Restricted Stock Units. Grantees of restricted
stock or RSUs do not recognize income at the time of the grant. When the award vests or is paid, grantees generally recognize ordinary
income in an amount equal to the fair market value of the stock or units at such time, and the Company will receive a corresponding deduction.
However, no later than 30 days after a participant receives an award of restricted stock, the participant may elect to recognize taxable
ordinary income in an amount equal to the fair market value of the shares at the time of receipt. Provided that the election is made in
a timely manner, when the restrictions on the shares lapse, the participant will not recognize any additional income. If the participant
forfeits the shares to the Company (e.g., upon the participant’s termination prior to vesting), the participant may not claim a
deduction with respect to the income recognized as a result of the election. Dividends paid with respect to unvested shares of restricted
stock generally will be taxable as ordinary income to the participant at the time the dividends are received.
Cash Awards. A participant will have taxable income at the time
a cash award becomes payable, and, if the participant has timely elected deferral to a later date, such later date. At that time, the
participant will recognize ordinary income equal to the value of the amount then payable.
Company Deduction and Section 162(m). In general,
Section 162(m) of the Code limits a publicly traded company’s federal income tax deduction for compensation in excess of $1 million
paid to its Chief Executive Officer, Chief Financial Officer and the next three highest-paid executive officers.
Withholding Taxes. The Company will generally be required
to withhold applicable taxes with respect to any ordinary income recognized by a participant in connection with awards made under the
2020 Plan. Whether or not such withholding is required, the Company will make such information reports to the Internal Revenue Service
as may be required with respect to any income (whether or not that of an employee) attributable to transactions involving awards.
New Plan Benefits
The benefits that will be awarded or paid
in the future under the 2020 Plan are not currently determinable. Such awards are within the discretion of the Compensation Committee,
and the Compensation Committee has not determined future awards or who might receive them. Therefore, a new plan benefits table is not
provided. As of May 30, 2023, the closing price of a share of the Company’s Common Stock was $4.03.
Recommendation
The Board of Directors recommends a vote “FOR”
approval of the amendment and restatement of the 2020 Plan, including the share increase thereunder.
Vote Required
This proposal must be approved by a majority of the
votes cast on the matter. As a result, abstentions and broker non-votes (if any) will be entirely excluded from the vote and will have
no effect on its outcome.
THE BOARD OF DIRECTORS
RECOMMENDS A VOTE “FOR” PROPOSAL NO. 3.
EQUITY COMPENSATION PLAN INFORMATION
The following table sets forth certain information, as of December
31, 2022, about the securities authorized for issuance under our equity compensation plans, which consisted of our 2020 Plan and our 2013
Employee Stock Purchase Plan. Upon adoption of the 2020 Plan, shares that remained available for grant under our prior 2012 Plan and shares
that were subject to outstanding awards under the 2012 Plan were included in the authorized shares available for grant under the 2020
Plan. Further, upon adoption of the 2020 Plan, the Company no longer grants new equity awards under the 2012 Plan.
Plan Category | |
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | | |
Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights | | |
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in First Column) | |
Equity compensation plans approved by security holders(1) | |
| 47,512 | | |
| 35,231.40 | | |
| 43,743 | |
Equity compensation plans not approved by security holders | |
| – | | |
| – | | |
| – | |
Total | |
| 47,512 | | |
| 35,231.40 | | |
| 43,743 | |
___________________
(1) |
Includes options outstanding representing 177 shares of Common Stock under the 2020 Plan. Also includes 47,335 RSUs subject to the 2020 Plan. |
SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Based on information available to us and filings with the SEC, the
following table sets forth certain information regarding the beneficial ownership (as defined by Rule 13d-3 under the Exchange Act) of
our outstanding Common Stock for (i) each of our directors, (ii) each of our NEOs, (iii) all of our directors and executive officers as
a group and (iv) persons known to us to beneficially own more than 5% of our outstanding Common Stock. The following information is presented
as of May 30, 2023 or such other date as may be reflected below.
Beneficial ownership and percentage ownership are determined in accordance
with the rules of the SEC and include voting or investment power with respect to shares of stock. This information does not necessarily
indicate beneficial ownership for any other purpose. Under these rules, shares of Common Stock not outstanding but deemed beneficially
owned by virtue of the right of a person to acquire them as of May 30, 2023, or within 60 days of May 30, 2023, are deemed outstanding
for the purpose of computing the percentage ownership of each person, but are not deemed outstanding for the purpose of computing the
percentage ownership of any other person.
Unless otherwise indicated and subject to applicable community property
laws, to our knowledge, each stockholder named in the following table possesses sole voting and investment power over their shares of
Common Stock, except for those jointly owned with that person’s spouse. Unless otherwise indicated below, the address of each person
listed on the table is c/o Phio Pharmaceuticals Corp., 257 Simarano Drive, Suite 101, Marlborough, MA 01752.
|
|
Shares Beneficially Owned |
|
Name and Address of Beneficial Owner |
|
Number (1) |
|
|
Percent of
Class (2) |
|
Greater Than 5% Holders: |
|
|
|
|
|
|
Intracoastal Capital, LLC (3) |
|
|
166,988 |
|
|
|
9.99% |
|
Directors and Named Executive Officers: |
|
|
|
|
|
|
Robert J. Bitterman (4) |
|
|
2,886 |
|
|
|
* |
|
Patricia A. Bradford |
|
|
– |
|
|
|
* |
|
Geert Cauwenbergh, Dr. Med. Sc.(5) |
|
|
2,786 |
|
|
|
* |
|
Robert Ferrara |
|
|
2,501 |
|
|
|
* |
|
Jonathan E. Freeman, Ph.D. (6) |
|
|
1,701 |
|
|
|
* |
|
Curtis A. Lockshin, Ph.D. (7) |
|
|
1,704 |
|
|
|
* |
|
All current directors and executive officers as a group (six persons) |
|
|
11,578 |
|
|
|
* |
|
* |
Indicates less than 1%. |
(1) |
Represents shares of Common Stock held as of May 30, 2023 plus shares of common stock that may be acquired upon the exercise of options and warrants within 60 days of May 30, 2023. |
(2) |
Based on 1,504,565 shares of Common Stock that were issued and outstanding as of May 30, 2023. Shares not outstanding but deemed beneficially owned by virtue of the right of a person to acquire them as of May 30, 2023, or within 60 days of May 30, 2023, are treated as outstanding only when determining the ownership and voting power for each person (or all directors and executive officers as a group). |
(3) |
Based solely on shares of common stock issuable upon the exercise of warrants held by Intracoastal Capital LLC (“Intracoastal”), Mitchell P. Kopin (“Mr. Kopin”) and Daniel B. Asher (“Mr. Asher”). Each of Intracoastal, Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership of 166,988 shares of common stock issuable upon the exercise of certain warrants held by Intracoastal. Certain of the warrants held by Intracoastal contain a blocker provision under which the holder thereof does not have the right to exercise its warrants to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% or 9.99% of the Company’s Common Stock. |
(4) |
Includes 5 stock options exercisable within 60 days of May 30, 2023. |
(5) |
Includes 46 stock options exercisable within 60 days of May 30, 2023. |
(6) |
Includes 1 stock option exercisable within 60 days of May 30, 2023. |
(7) |
Includes 4 stock options exercisable within 60 days of May 30, 2023. |
OTHER BUSINESS
We know of no other matters to be submitted to a vote of stockholders
at the Annual Meeting. If any other matter is properly brought before the Annual Meeting or any adjournment thereof, it is the intention
of the persons named in the enclosed proxy to vote the shares they represent in accordance with their judgment. In order for any stockholder
to nominate a candidate or to submit a proposal for other business to be acted upon at a given annual meeting, he or she must provide
timely written notice to our corporate Secretary in the form prescribed by our Bylaws, as described below.
STOCKHOLDER PROPOSALS
Stockholder proposals intended to be included in the 2024 annual meeting
proxy materials pursuant to Rule 14a-8 must be received by the Secretary of the Company no later than February 10, 2024, which is 120
calendar days before the anniversary of the date this Proxy Statement for the Annual Meeting is released to stockholders, or otherwise
as permitted by applicable law (the “Proxy Deadline”). The form and substance of these proposals must satisfy the requirements
established by the Company’s Bylaws and the SEC, and the timing for the submission of any such proposals may be subject to change
as a result of changes in SEC rules and regulations.
Additionally, stockholders who intend to present a stockholder proposal
or nominate a director at the 2024 annual meeting must provide the Secretary of the Company with written notice of the proposal not fewer
than 90 nor more than 120 days prior to the anniversary date of the Annual Meeting, provided, however, that if the 2024 annual
meeting date is more than 30 days before or after the anniversary date of the Annual Meeting, then stockholders must provide notice on
or before 10 days after the day on which the date of the 2024 annual meeting is first disclosed in a public announcement. Notice must
be tendered in the proper form prescribed by our Bylaws. Proposals not meeting the requirements set forth in our Bylaws will not be entertained
at the meeting. If a stockholder fails to meet these deadlines and fails to satisfy the requirements of Rule 14a-4 of the Exchange Act,
we may exercise discretionary voting authority under proxies we solicit to vote on any such proposal as we determine appropriate. In addition
to satisfying the deadlines in the advance notice provisions of our bylaws, a stockholder who intends to solicit proxies in support of
nominees submitted under these advance notice provisions for the 2024 annual meeting must provide the notice required under Rule 14a-19
of the Exchange Act to our Secretary in writing not later than May 21, 2024.
Additionally, any stockholder seeking to recommend a director candidate
or any director candidate who wishes to be considered by the Nominating Committee, the committee that recommends a slate of nominees to
the Board for election at each annual meeting, must provide the Secretary of the Company with a completed and signed biographical questionnaire
on or before the Proxy Deadline. Stockholders can obtain a copy of this questionnaire from the Secretary of the Company upon written request.
The Nominating Committee is not required to consider director candidates received after this date or without the required questionnaire.
The Nominating Committee will consider all director candidates who comply with these requirements and will evaluate these candidates using
the criteria described above under the caption, “Nomination of Directors.” Director candidates who are then approved by the
Board will be included in the Company’s proxy statement for that annual meeting.
DELIVERY OF PROXY MATERIALS
Our Annual Report to stockholders for the fiscal year ended December
31, 2022, including audited financial statements and the notes thereto, accompanies this Proxy Statement. Copies of our Annual Report
on Form 10-K for fiscal 2022 and the exhibits thereto are available from the Company without charge upon written request of a stockholder.
Copies of these materials are also available online through the SEC at www.sec.gov. The Company may satisfy SEC rules regarding
delivery of proxy materials, including the Proxy Statement, Annual Report and Notice, by delivering a single Notice and, if applicable,
a single set of proxy materials to an address shared by two or more Company stockholders. This delivery method can result in meaningful
cost savings for the Company. In order to take advantage of this opportunity, the Company may deliver only one Notice and, if applicable,
a single set of proxy materials to multiple stockholders who share an address, unless contrary instructions are received prior to the
mailing date. Similarly, if you share an address with another stockholder and have received multiple copies of our Notice and/or other
proxy materials, you may write or call us at the address and phone number below to request delivery of a single copy of the Notice and,
if applicable, other proxy materials in the future. We undertake to deliver promptly upon written or oral request a separate copy of the
Notice and, if applicable, other proxy materials, as requested, to a stockholder at a shared address to which a single copy of the Notice
and/or other proxy materials was delivered. If you hold stock as a record stockholder and prefer to receive separate copies of a Notice
and, if applicable, other proxy materials either now or in the future, please contact the Company at 257 Simarano Drive, Suite 101, Marlborough,
MA 01752 or by telephone at (508) 767-3861. If your stock is held through a brokerage firm or bank and you prefer to receive separate
copies of a Notice and, if applicable, other proxy materials either now or in the future, please contact your brokerage firm or bank.
EACH STOCKHOLDER IS URGED TO COMPLETE, DATE,
SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY.
Appendix A
PHIO PHARMACEUTICALS CORP.
2020 LONG TERM INCENTIVE PLAN
(a)
Successor to Prior Plan. This Plan is the successor to the Phio Pharmaceuticals Corp. 2012 Long Term Incentive Plan, as
amended (the “Prior Plan”). From and after 12:01 a.m. Eastern time on the Effective Date, no additional stock awards
will be granted under the Prior Plan.
(b)
Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards.
(c)
Available Awards. This Plan provides for the grant of the following Awards: (i) Incentive Stock Options; (ii) Nonstatutory
Stock Options; (iii) Stock Appreciation Rights; (iv) Restricted Stock Awards; (v) Restricted Stock Unit Awards; (vi) Performance Stock
Awards; and (vii) Performance Cash Awards.
(d)
Purpose. This Plan, through the granting of Awards, is intended to help the Company secure and retain the services of eligible
award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide
a means by which the eligible award recipients may benefit from increases in the value of the Common Stock.
(a)
Administration by Board. The Board will administer this Plan. The Board may delegate administration of this Plan to a Committee
or Committees, as provided in Section 2(d).
(b)
Powers of Board. The Board will have the power, subject to, and within the limitations of, the express provisions of this
Plan:
(i)
To determine: (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted;
(D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive
cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the
Fair Market Value applicable to a Stock Award.
(ii)
To construe and interpret this Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration
of this Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in this Plan or
in any Award Document or in the written terms of a Performance Cash Award, in a manner and to the extent it will deem necessary or expedient
to make this Plan or Award fully effective.
(iii)
To settle all controversies regarding this Plan and Awards granted under it.
(iv)
To accelerate, in whole or in part, or to extend, in whole or in part, the time during which an Award may be exercised or vest,
or at which cash or shares of Common Stock may be issued.
(v)
To suspend or terminate this Plan at any time. Except as otherwise provided in this Plan or an Award Document, suspension or termination
of this Plan will not materially impair a Participant’s rights under his or her then-outstanding Award without his or her written
consent except as provided in subsection (viii) below.
(vi) To
amend this Plan in any respect the Board deems necessary or advisable, including, without limitation, adopting amendments relating to
Incentive Stock Options and nonqualified deferred compensation under Section 409A of the Code and/or making this Plan or Awards granted
under this Plan exempt from or compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements
for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If required
by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company
will seek stockholder approval of any amendment of this Plan that (A) materially increases the number of shares of Common Stock available
for issuance under this Plan, (B) materially expands the class of individuals eligible to receive Awards under this Plan, (C) materially
increases the benefits accruing to Participants under this Plan, (D) materially reduces the price at which shares of Common Stock may
be issued or purchased under this Plan, (E) materially extends the term of this Plan, or (F) materially expands the types of Awards available
for issuance under this Plan. Except as otherwise provided in this Plan (including subsection (viii) below) or an Award Document, no amendment
of this Plan will materially impair a Participant’s rights under an outstanding Award without the Participant’s written consent.
(vii) To
submit any amendment to this Plan for stockholder approval, including, but not limited to, amendments to this Plan intended to satisfy
the requirements of (A) Section 422 of the Code regarding “incentive stock options” or (B) Rule 16b-3 of the Exchange Act
or any successor rule, if applicable.
(viii) To
approve forms of Award Documents for use under this Plan and to amend the terms of any one or more outstanding Awards, including, but
not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Documents for such
Awards, subject to any specified limits in this Plan that are not subject to Board discretion. A Participant’s rights under any
Award will not be impaired by any such amendment unless the Company requests the consent of the affected Participant, and the Participant
consents in writing. However, a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board,
in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights. In
addition, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected
Participant’s consent (A) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code,
(B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the
qualified status of the Award as an Incentive Stock Option under Section 422 of the Code, (C) to clarify the manner of exemption from,
or to bring the Award into compliance with, Section 409A of the Code, or (D) to comply with other applicable laws or listing requirements.
(ix) Generally,
to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company
and that are not in conflict with the provisions of this Plan and/or Award Documents.
(x) To
adopt such procedures and sub-plans as are necessary or appropriate (A) to permit or facilitate participation in this Plan by persons
eligible to receive Awards under this Plan who are not citizens of, subject to taxation by, or employed outside, the United States or
(B) to allow Awards to qualify for special tax treatment in a jurisdiction other than the United States. Board approval will not be necessary
for immaterial modifications to this Plan or any Award Document that are required for compliance with the laws of the relevant jurisdiction.
(c)
Minimum Vesting. Notwithstanding any other provision of this Plan, Awards granted under this Plan may not become exercisable,
vest or settle, in whole or in part, prior to the one-year anniversary of the date of grant, except that (1) the Board may provide that
Awards become exercisable, vest or settle prior to such date in the event of the Participant’s death or disability or in connection
with a Change in Control, and (2) Awards to Non-Employee Directors may vest on the Company’s next annual meeting of stockholders
(provided that such annual meetings are at least fifty (50) weeks apart). Notwithstanding the foregoing, up to 5% of the aggregate number
of Shares authorized for issuance under this Plan (as described in Section 3(a)(1) hereof) may be issued without regard to the restrictions
of the foregoing sentence.
(d)
Delegation to Committee.
(i)
General. The Board may delegate some or all of the administration of this Plan to a Committee or Committees. If administration
of this Plan is delegated to a Committee, the Committee will have, in connection with the administration of this Plan, the powers theretofore
possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any
of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the
Committee or subcommittee). Any delegation of administrative powers will be reflected in the charter of the Committee to which the delegation
is made, or resolutions, not inconsistent with the provisions of this Plan, adopted from time to time by the Board or Committee (as applicable).
The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to any subcommittee. Unless
otherwise provided by the Board, delegation of authority by the Board to a Committee, or to an Officer or employee pursuant to Section
2(e), does not limit the authority of the Board, which may continue to exercise any authority so delegated and may concurrently administer
this Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.
(ii)
Rule 16b-3 Compliance. The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3
of the Exchange Act.
(e)
Delegation to an Officer. The Board may delegate to one (1) or more Officers the authority to do one or both of the following,
to the maximum extent permitted by applicable law: (i) designate Employees who are not Officers to be recipients of Stock Awards and the
terms of such Stock Awards; and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such
Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock
that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.
Any such Stock Awards will be granted on a form that is substantially the same as the form of Stock Award Document approved by the Committee
or the Board for use in connection with such Stock Awards, unless otherwise provided for in the resolutions approving the delegation authority.
(f)
Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board (or a duly authorized
Committee, subcommittee or Officer exercising powers delegated by the Board under this Section 2) in good faith will not be subject
to review by any person and will be final, binding and conclusive on all persons.
|
3. |
SHARES SUBJECT TO THIS PLAN. |
(a)
Share Reserve.
(i)
Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that
may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 225,500 shares
of Common Stock plus (A) any shares of Common Stock that remain available for grant under the Prior Plan as of the Effective Date and
(B) any shares of Common Stock subject to outstanding awards under the Prior Plan as of the Effective Date (such outstanding awards the
“Prior Plan Awards”) that on or after the Effective Date are forfeited, terminated, expire or otherwise lapse without
being exercised (to the extent applicable), or are settled in cash (the “Share Reserve”).
(ii)
For clarity, the Share Reserve is a limitation on the number of shares of Common Stock that may be issued under this Plan. As a
single share may be subject to grant more than once (e.g., if a share subject to a Stock Award is forfeited, it may be made subject to
grant again as provided in Section 3(b) below), the Share Reserve is not a limit on the number of Stock Awards that can be granted.
(iii)
Shares may be issued under the terms of this Plan in connection with a merger or acquisition as permitted by NASDAQ Listing Rule
5635(c), NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not
reduce the number of shares available for issuance under this Plan.
(iv)
Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate Fair Market Value on the date of grant of
Shares subject to Awards granted under this Plan, together with any cash compensation paid or payable, during any calendar year to any
one Non-Employee Director shall not exceed $500,000; provided, however, that in the calendar year in which a Non-Employee Director first
joins the Board or is designated as Chairman of the Board, such maximum dollar value may be up to two hundred percent (200%) of the dollar
value set forth in the foregoing limit. The limitation described in this Section shall be determined without regard to amounts paid to
a Non-Employee Director during or for any period in which such individual was an employee or consultant, and any severance and other payments
paid to a Non-Employee Director for such director’s prior or current service to the Company or any Subsidiary other than serving
as a director shall not be taken into account in applying the limit provided above. For the avoidance of doubt, any compensation that
is deferred shall be counted toward this limit for the year in which it was first earned, and not when paid or settled.
(b)
Reversion of Shares to the Share Reserve. If a Stock Award or any portion of a Stock Award expires, is cancelled or forfeited
or otherwise terminates without all of the shares covered by the Stock Award having been issued, then the shares of Common Stock subject
to the Stock Award (or portion thereof) that expires, is cancelled or forfeited or otherwise terminates shall revert and again be available
for issuance under this Plan. If any shares of Common Stock are repurchased by the Company using proceeds from the exercise or purchase
price of a Stock Award, or retained because the Stock Award (or a portion thereof) is settled in cash (i.e., the Participant receives
cash rather than stock), then the shares that are repurchased or retained shall not revert and will not become available for issuance
under this Plan. Any shares retained and not issued by the Company in satisfaction of tax withholding obligations on a Stock Award or
as consideration for the exercise or purchase price of a Stock Award will reduce the number of shares of Common Stock that are available
for issuance under this Plan and such shares shall not be available for issuance under this Plan.
(c)
Incentive Stock Option Limit. Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate maximum
number of shares of Common Stock that may be issued on the exercise of Incentive Stock Options will be 1,200,000 shares of Common Stock.
(d)
Source of Shares. The stock issuable under this Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise or shares classified as treasury shares.
(a)
Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent
corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code).
Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants.
(b)
Ten Percent Stockholders. A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price
of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of
five (5) years from the date of grant.
|
5. |
PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS. |
Each Option or SAR will be
in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive
Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates
will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as
an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify
as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The
provisions of separate Options or SARs need not be identical; provided, however, that each Award Document will conform to (through incorporation
of provisions hereof by reference in the applicable Award Document or otherwise) the substance of each of the following provisions:
(a)
Term. Subject to Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the
expiration of 10 years from the date of its grant or such shorter period specified in the Award Document.
(b)
Exercise Price. Subject to Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each
Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award
is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair
Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another
option or stock appreciation right pursuant to a corporate transaction and in a manner consistent with the provisions of Section 409A
of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents.
(c)
Purchase Price for Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid,
to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of
payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment
(or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular
method of payment. The purchase price shall be denominated in U.S. dollars. The permitted methods of payment are as follows:
(i)
by cash, check, bank draft or money order payable to the Company;
(ii)
pursuant to a program developed under Regulation T as promulgated by the United States Federal Reserve Board or a successor regulation,
or a similar rule in a foreign jurisdiction of domicile of a Participant, that, prior to or contemporaneously with the issuance of the
stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions
to pay the aggregate exercise price to the Company from the proceeds of sale of such stock;
(iii)
by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;
(iv)
by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable
upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided,
however, that the Company will accept cash or other payment from the Participant to the extent of any remaining balance of the aggregate
exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject
to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise
price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares
are withheld to satisfy tax withholding obligations; or
(v)
in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Document.
(d)
Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise
to the Company in compliance with the provisions of the Stock Appreciation Right Award Document evidencing such SAR. The appreciation
distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market
Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in
which the Participant is vested under such SAR (with respect to which the Participant is exercising the SAR on such date), over (B) the
aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.
The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration,
as determined by the Board and contained in the Award Document evidencing such SAR.
(e)
Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability
of Options and SARs as the Board determines. In the absence of such a determination by the Board to the contrary, the following restrictions
on the transferability of Options and SARs will apply:
(i)
Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution
(or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant.
The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as
explicitly provided herein, neither an Option nor a SAR may be transferred for consideration.
(ii)
Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred
pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as
permitted by U.S. Treasury Regulation 1.421-1(b)(2) or other applicable law. If an Option is an Incentive Stock Option, such Option may
be deemed to be a Nonstatutory Stock Option as a result of such transfer.
(iii)
Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering
written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death
of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting
from such exercise. In the absence of such a designation, the executor or administrator of the Participant’s estate will be entitled
to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may
prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent
with the provisions of applicable laws.
(f)
Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become
exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions
on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria)
as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f)
are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be
exercised.
(g)
Termination of Continuous Service. Except as otherwise provided in the applicable Award Document, or other agreement between
the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the
Participant’s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was
entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of
(i) the date three (3) months following the termination of the Participant’s Continuous Service and (ii) the expiration of the term
of the Option or SAR as set forth in the applicable Award Document. If, after termination of Continuous Service, the Participant does
not exercise his or her Option or SAR within the applicable time frame, the Option or SAR will terminate.
(h)
Extension of Termination Date. Except as otherwise provided in the applicable Award Document, or other agreement between
the Participant and the Company, if the exercise of an Option or SAR following the termination of the Participant’s Continuous Service
(other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because
the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will
terminate on the earlier of (i) the expiration of a total period of three (3) months (that need not be consecutive) after the termination
of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration
requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Document. In addition, unless
otherwise provided in a Participant’s applicable Award Document, or other agreement between the Participant and the Company, if
the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous
Service (other than for Cause) would violate the Company’s insider trading policy, and the Company does not waive the potential
violation of the policy or otherwise permit the sale, or allow the Participant to surrender shares of Common Stock to the Company in satisfaction
of any exercise price and/or any withholding obligations under Section 8(g), then the Option or SAR will terminate on the earlier
of (i) the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination exercise period after
the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the
Option or SAR would not be in violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option
or SAR as set forth in the applicable Award Document.
(i)
Disability of Participant. Except as otherwise provided in the applicable Award Document, or other agreement between the
Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability,
the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR
as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months
following such termination of Continuous Service, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable
Award Document. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable
time frame, the Option or SAR (as applicable) will terminate.
(j)
Death of Participant. Except as otherwise provided in the applicable Award Document, or other agreement between the Participant
and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the
Participant dies within the period (if any) specified in this Plan or the applicable Award Document, or other agreement between the Participant
and the Company, for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death),
then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death)
by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a
person designated to exercise the Option or SAR upon the Participant’s death, but only within the period ending on the earlier of
(i) the date 18 months following the date of death, and (ii) the expiration of the term of such Option or SAR as set forth in the applicable
Award Document. If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option
or SAR will terminate.
(k)
Termination for Cause. Except as explicitly provided otherwise in a Participant’s Award Document or other individual
written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated
for Cause, the Option or SAR will terminate upon the date on which the event giving rise to the termination for Cause first occurred,
and the Participant will be prohibited from exercising his or her Option or SAR from and after the date on which the event giving rise
to the termination for Cause first occurred (or, if required by law, the date of termination of Continuous Service). If a Participant’s
Continuous Service is suspended pending an investigation of the existence of Cause, all of the Participant’s rights under the Option
or SAR will also be suspended during the investigation period.
(l)
Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the U.S.
Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at
least 6 months following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the
provisions of the U.S. Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Change
in Control in which such Option or SAR is not assumed, continued, or substituted, or (iii) upon the non-exempt Employee’s retirement
(as such term may be defined in the non-exempt Employee’s applicable Award Document, in another agreement between the non-exempt
Employee and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines),
the vested portion of any Options and SARs may be exercised earlier than 6 months following the date of grant. The foregoing provision
is intended to operate so that any income derived by a non-exempt Employee in connection with the exercise or vesting of an Option or
SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the U.S. Worker Economic
Opportunity Act to ensure that any income derived by a non-exempt Employee in connection with the exercise, vesting or issuance of any
shares under any other Stock Award will be exempt from such employee’s regular rate of pay, the provisions of this paragraph will
apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Documents.
(m)
No Repricing. Neither an Option nor SAR may be modified to reduce the exercise price thereof nor may a new Option, SAR or
other Award at a lower price be substituted or exchanged for a surrendered Option or SAR (other than adjustments or substitutions in accordance
with Section 9(a) relating to Capitalization Adjustments), unless such action is approved by the stockholders of the Company.
|
6. |
PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS. |
(a)
Restricted Stock Awards. Each Restricted Stock Award Document will be in such form and will contain such terms and conditions
as the Board deems appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common
Stock may be (x) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted
Stock Award lapse, or (y) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.
The terms and conditions of Restricted Stock Award Documents may change from time to time, and the terms and conditions of separate Restricted
Stock Award Documents need not be identical. Each Restricted Stock Award Document will conform to (through incorporation of the provisions
hereof by reference in the agreement or otherwise) the substance of each of the following provisions:
(i)
Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable
to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services)
that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.
(ii)
Vesting. Shares of Common Stock awarded under the Restricted Stock Award Document may be subject to forfeiture to the Company
in accordance with a vesting schedule and subject to such conditions as may be determined by the Board.
(iii)
Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company
may receive through a forfeiture condition or a repurchase right, any or all of the shares of Common Stock held by the Participant that
have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Document.
(iv)
Transferability. Common Stock issued pursuant to an Award, and rights to acquire shares of Common Stock under the Restricted
Stock Award Document, will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock
Award Document, as the Board determines in its sole discretion, so long as such Common Stock remains subject to the terms of the Restricted
Stock Award Document.
(v)
Dividends. Any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply
to the shares subject to the Restricted Stock Award to which they relate.
(b)
Restricted Stock Unit Awards. Each Restricted Stock Unit Award Document will be in such form and will contain such terms
and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Documents may change from time
to time, and the terms and conditions of separate Restricted Stock Unit Award Documents need not be identical. Each Restricted Stock Unit
Award Document will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance
of each of the following provisions:
(i)
Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any,
to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration
to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form
of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.
(ii)
Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions
to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.
(iii)
Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent,
any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award
Document.
(iv)
Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate,
may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to
a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.
(v)
Dividend Equivalents. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted
Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Document. At the sole discretion of the
Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in
such manner as determined by the Board. Any dividend equivalents and/or additional shares covered by the Restricted Stock Unit Award credited
by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit
Award Document to which they relate.
(vi)
Termination of Participant’s Continuous Service. Except as otherwise provided in the applicable Restricted Stock Unit
Award Document, or other agreement between the Participant and the Company, such portion of the Restricted Stock Unit Award that has not
vested will be forfeited upon the Participant’s termination of Continuous Service.
(c)
Performance Awards.
(i)
Performance Stock Awards. A Performance Stock Award is a Stock Award that is payable (including that may be granted, vest
or exercised) contingent upon the attainment during a Performance Period of the achievement of certain performance goals. A Performance
Stock Award may, but need not, require the completion of a specified period of Continuous Service. The length of any Performance Period,
the performance goals to be achieved during the Performance Period, and the measure of whether and to what degree such performance goals
have been attained will be conclusively determined by the Committee, the Board, or an authorized Officer, in its sole discretion. In addition,
to the extent permitted by applicable law and the applicable Award Document, the Board may determine that cash may be used in payment
of Performance Stock Awards.
(ii)
Performance Cash Awards. A Performance Cash Award is a cash award that is granted and/or becomes payable contingent upon
the attainment during a Performance Period of the achievement of certain performance goals. A Performance Cash Award may also require
the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award, the length of any Performance
Period, the performance goals to be achieved during the Performance Period, and the measure of whether and to what degree such performance
goals have been attained will be conclusively determined by the Committee, the Board, or an authorized Officer, in its sole discretion.
The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant
to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in
part in cash or other property.
(iii)
Board Discretion. The Committee, the Board, or an authorized Officer, as the case may be, retains the discretion to define
the manner of calculating the performance criteria it selects to use for a Performance Period.
|
7. |
COVENANTS OF THE COMPANY. |
(a)
No Obligation to Notify or Minimize Taxes. The Company will have no duty or obligation to any Participant to advise such
holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise
advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The
Company has no duty or obligation to, and does not undertake to, provide tax advice or to minimize the tax consequences of an Award to
the holder of such Award.
(b)
Securities Law Compliance. The Company will seek to obtain from each regulatory commission or agency having jurisdiction
over this Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the
Stock Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act this Plan, any
Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable
cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary
for the lawful issuance and sale of Common Stock under this Plan, the Company will be relieved from any liability for failure to issue
and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible
for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be
in violation of any applicable securities law.
(a)
Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will
constitute general funds of the Company.
(b)
Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant
will be deemed completed as of the latest date that all necessary corporate action has occurred and all material terms of the Award (including,
in the case of stock options, the exercise price thereof) are fixed, unless otherwise determined by the Board, regardless of when the
documentation evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate
records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise
price, vesting schedule or number of shares) that are inconsistent with those in the Award Document as a result of a clerical error in
the papering of the Award Document, the corporate records will control and the Participant will have no legally binding right to the incorrect
term in the Award Document.
(c)
Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect
to, any shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise
of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii) the issuance of the Common Stock
subject to such Stock Award has been entered into the books and records of the Company.
(d)
No Employment or Other Service Rights. Nothing in this Plan, any Award Document or any other instrument executed thereunder
or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or
an Affiliate in the capacity in effect at the time the Award was granted or any other capacity or will affect the right of the Company
or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, including, but not limited
to, Cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate,
or (iii) the service of a Director pursuant to the organizational documents of the Company or an Affiliate (including articles of incorporation
and bylaws), and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as
the case may be.
(e)
Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his
or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee
of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of
absence), or the Participant’s role or primary responsibilities are changed to a level that, in the Board’s determination
does not justify the Participant’s unvested Awards, and such reduction or change occurs after the date of grant of any Award to
the Participant, the Board has the right in its sole discretion to (i) make a corresponding reduction in the number of shares or cash
amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment,
and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event
of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.
(f)
Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of grant)
of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar
year (under all plans of the Company and any Affiliates) exceeds USD$100,000 (or such other limit established in the Code) or otherwise
does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to
the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding
any contrary provision of the applicable Option Agreement(s).
(g)
Withholding Obligations. Unless prohibited by the terms of an Award Document, the Company may, in its sole discretion, satisfy
any national, state, local or other tax withholding obligation relating to an Award by any of the following means or by a combination
of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common
Stock issued or otherwise issuable to the Participant in connection with the Award (only up to the amount permitted that will not cause
an adverse accounting consequence or cost); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any
amounts otherwise payable to the Participant, including proceeds from the sale of shares of Common Stock issued pursuant to a Stock Award;
or (v) by such other method as may be set forth in the Award Document.
(h)
Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or
document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto), or posted on the Company’s
intranet (or other shared electronic medium controlled by the Company to which the Participant has access).
(i)
Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery
of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and
may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance
with Section 409A of the Code (to the extent applicable to a Participant). Consistent with Section 409A of the Code, the Board may provide
for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is authorized to
make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments,
following the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the
provisions of this Plan and in accordance with applicable law.
(j)
Compliance with Section 409A. Unless otherwise expressly provided for in an Award Document, or other agreement between the
Participant and the Company, this Plan and Award Documents will be interpreted to the greatest extent possible in a manner that makes
this Plan and the Awards granted hereunder exempt from Section 409A of the Code, to the extent that Section 409A of the Code is applicable
to an Award, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted
hereunder is subject to Section 409A of the Code, the Award Document evidencing such Award will incorporate the terms and conditions necessary
to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Document is silent on terms necessary
for compliance, such terms are hereby incorporated by reference into the Award Document. Notwithstanding anything to the contrary in this
Plan (and unless the Award Document specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant
holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee”
for purposes of Section 409A of the Code and the Participant is otherwise subject to Section 409A of the Code, no distribution or payment
of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to
alternative definitions thereunder) will be issued or paid before the date that is six (6) months following the date of such Participant’s
“separation from service” or, if earlier, the date of the Participant’s death, unless such distribution or payment can
be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after
such six (6) month period elapses, with the balance paid thereafter on the original schedule.
(i)
Clawback/Recovery. All Awards granted under this Plan will be subject to recoupment in accordance with any clawback policy
that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the
Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or
other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Document as
the Board determines necessary or appropriate, including, but not limited to, a reacquisition right in respect of previously acquired
shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy
will be an event giving rise to a right to resign for “good reason” or “constructive termination” (or similar
term) under any agreement with the Company or an Affiliate.
|
9. |
ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS. |
(a)
Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately
adjust: (i) the class(es) and maximum number of securities subject to this Plan pursuant to Section 3(a); (ii) the class(es) and
maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c); and
(iii) the class(es) and number of securities or other property and value (including price per share of stock) subject to outstanding Stock
Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.
(b)
Dissolution or Liquidation. Except as otherwise provided in the Stock Award Document, or other agreement between the Participant
and the Company, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting
of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will
terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s
repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the
holder of such Stock Award is providing Continuous Service; provided, however, that the Board may, in its sole discretion, cause some
or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock
Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.
(c)
Change in Control. The following provisions will apply to Awards in the event of a Change in Control unless otherwise provided
in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless
otherwise expressly provided by the Board at the time of grant of an Award. In the event of a Change in Control, then, notwithstanding
any other provision of this Plan, the Board will take one or more of the following actions with respect to each outstanding Award, contingent
upon the closing or completion of the Change in Control:
(i)
arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company)
to assume or continue the Award or to substitute a similar award for the Award (including, but not limited to, an award to acquire the
same consideration per share paid to the stockholders of the Company pursuant to the Change in Control);
(ii)
arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant
to the Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company);
(iii)
accelerate the vesting, in whole or in part, of the Award (and, if applicable, the time at which the Award may be exercised) to
a date prior to the effective time of such Change in Control as the Board will determine (or, if the Board will not determine such a date,
to the date that is 5 days prior to the effective date of the Change in Control), with such Award terminating if not exercised (if applicable)
at or prior to the effective time of the Change in Control, and with such exercise reversed if the Change in Control does not become effective;
(iv)
arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Award;
(v)
cancel or arrange for the cancellation of the Award, to the extent not vested or not exercised prior to the effective time of the
Change in Control, in exchange for such cash consideration, if any, as the Board, in its reasonable determination, may consider appropriate
as an approximation of the value of the canceled Award, taking into account the value of the Common Stock subject to the canceled Award,
the possibility that the Award might not otherwise vest in full, and such other factors as the Board deems relevant; and
(vi)
cancel or arrange for the cancellation of the Award, to the extent not vested or not exercised prior to the effective time of the
Change in Control, in exchange for a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value
in the Change in Control of the property the Participant would have received upon the exercise of the Award immediately prior to the effective
time of the Change in Control, over (B) any exercise price payable by such holder in connection with such exercise.
The Board need not take the
same action or actions with respect to all Awards or portions thereof or with respect to all Participants. The Board may take different
actions with respect to the vested and unvested portions of an Award.
In the absence of any affirmative
determination by the Board at the time of a Change in Control, each outstanding Award will be assumed or an equivalent Award will be substituted
by such successor corporation or a parent or subsidiary of such successor corporation (the “Successor Corporation”),
unless the Successor Corporation does not agree to assume the Award or to substitute an equivalent Award, in which case the vesting of
such Award will accelerate in its entirety (along with, if applicable, the time at which the Award may be exercised) to a date prior to
the effective time of such Change in Control as the Board will determine (or, if the Board will not determine such a date, to the date
that is 5 days prior to the effective date of the Change in Control), with such Award terminating if not exercised (if applicable) at
or prior to the effective time of the Change in Control, and with such exercise reversed if the Change in Control does not become effective.
(d)
Acceleration of Awards upon a Change in Control. An Award may be subject to additional acceleration of vesting and exercisability
upon or after a Change in Control as may be provided in the Award Document for such Award or as may be provided in any other written agreement
between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur.
|
10. |
TERMINATION OR SUSPENSION OF THIS PLAN. |
The Board or the Compensation
Committee may suspend or terminate this Plan at any time. This Plan will have no fixed expiration date; provided, however, that no Incentive
Stock Option may be granted more than 10 years after the later of (i) the Adoption Date and (ii) the adoption by the Board of any amendment
to this Plan that constitutes the adoption of a new plan for purposes of Section 422 of the Code. No Awards may be granted under this
Plan while this Plan is suspended or after it is terminated.
|
11. |
EFFECTIVE DATE OF PLAN; TIMING OF FIRST GRANT OR EXERCISE. |
No Stock Award may be exercised
(or, in the case of a Restricted Stock Award, Restricted Stock Unit Award, or Performance Stock Award, may be granted) and no Performance
Cash Award may be settled unless and until this Plan has been approved by the stockholders of the Company, which approval will be within
12 months before or after the Adoption Date. The Plan was approved by the Board on the Adoption Date and shall become effective on the
Effective Date, subject to stockholder approval on such date. Subject to earlier termination as provided in Section 10, no new
Stock Awards may be granted under this Plan on or after October 8, 2030; provided, however, that Stock Awards outstanding on such date
shall remain subject to the terms of the Plan and any applicable Award Document.
The laws of the State of Delaware
will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s
conflict of laws rules.
As used in this Plan, the
following definitions will apply to the capitalized terms indicated below:
(a)
“Adoption Date” means August 5, 2020, which is the date of adoption of this Plan by the Board.
(b)
“Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the
Company, as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times
at which “parent” or “subsidiary” status is determined within the foregoing definition.
(c)
“Award” means a Stock Award or a Performance Cash Award.
(d)
“Award Document” means a written agreement between the Company and a Participant, or a written notice issued
by the Company to a Participant, evidencing the terms and conditions of an Award.
(e)
“Board” means the Board of Directors of the Company.
(f)
“Capital Stock” means each and every class of common stock of the Company, regardless of the number of votes
per share.
(g)
“Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the
Common Stock subject to this Plan or subject to any Stock Award after the Adoption Date without the receipt of consideration by the Company
through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash,
large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change
in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board
Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment.
(h)
“Cause” will have the meaning ascribed to such term in any written agreement between the Participant and the
Company or any Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the
occurrence of any of the following events: (i) Participant’s failure substantially to perform his or her duties and responsibilities
to the Company or any Affiliate or violation of a policy of the Company or any Affiliate; (ii) Participant’s commission of any act
of fraud, embezzlement, dishonesty or any other misconduct that has caused or is reasonably expected to result in injury to the Company
or any Affiliate; (iii) unauthorized use or disclosure by Participant of any proprietary information or trade secrets of the Company or
any other party to whom the Participant owes an obligation of nondisclosure as a result of his or her relationship with the Company or
any Affiliate; or (iv) Participant’s breach of any of his or her obligations under any written agreement or covenant with the Company
or any Affiliate. The determination as to whether a Participant is being terminated for Cause will be made in good faith by the Company
and will be final and binding on the Participant. Any determination by the Company that the Continuous Service of a Participant was terminated
with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the
rights or obligations of the Company, any Affiliate or such Participant for any other purpose.
(i)
“Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of
any one or more of the following events:
(i)
any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction;
(ii)
there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately
after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto
do not Own, directly or indirectly, either (A) outstanding voting securities representing 50% or more of the combined outstanding voting
power of the surviving Entity in such merger, consolidation or similar transaction or (B) 50% or more of the combined outstanding voting
power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same
proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;
(iii)
there is consummated a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the
Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets
of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned
by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such sale, lease, license or other disposition; or
(iv)
individuals who, on the Adoption Date, are members of the Board (the “Incumbent Board”) cease for any reason
to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for
election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office,
such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.
Notwithstanding the foregoing
definition or any other provision of this Plan, (A) the term Change in Control will not include a sale of assets, merger or other transaction
effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous
term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition
with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term
is set forth in such an individual written agreement, the foregoing definition will apply.
If required for compliance
with Section 409A of the Code, in no event will a Change in Control be deemed to have occurred if such transaction is not also a “change
in the ownership or effective control of” the Company or “a change in the ownership of a substantial portion of the assets
of” the Company as determined under U.S. Treasury Regulation Section 1.409A-3(i)(5) (without regard to any alternative definition
thereunder). The Board may, in its sole discretion and without a Participant’s consent, amend the definition of “Change in
Control” to conform to the definition of “Change in Control” under Section 409A of the Code, and the regulations thereunder.
(j)
“Code” means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance
thereunder.
(k)
“Committee” means a committee of one (1) or more Directors to whom authority has been delegated by the Board
in accordance with Section 2(d).
(l)
“Compensation Committee” means the Compensation Committee of the Board.
(m)
“Common Stock” means the common stock of the Company.
(n)
“Company” Phio Pharmaceuticals Corp., a Delaware corporation.
(o)
“Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render
consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate
and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director
to be considered a “Consultant” for purposes of this Plan. Notwithstanding the foregoing, a person is treated as a Consultant
under this Plan only if a Form Registration Statement on Form S-8 or a successor form under the Securities Act is available to register
either the offer or the sale of the Company’s securities to such person.
(p)
“Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service
to the Company or an Affiliate as an Employee, Consultant or Director or a change in the Entity for which the Participant renders such
service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will
not terminate a Participant’s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant
of an Affiliate or to a Director will not constitute an interruption of Continuous Service. If the Entity for which a Participant is rendering
services ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service
will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board
or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be
considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave,
military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. In addition, if
required for exemption from or compliance with Section 409A of the Code, the determination of whether there has been a termination of
Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of “separation
from service” as defined under U.S. Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).
A leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided
in the applicable Award Document, the Company’s leave of absence policy, in the written terms of any leave of absence agreement
or policy applicable to the Participant, or as otherwise required by law.
(q)
“Director” means a member of the Board.
(r) “Disability”
means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any
medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to
last for a continuous period of not less than 12 months as provided in Sections 22(e)(3) and 409A(a)(2)(C)(i) of the Code, and will be
determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.
(s)
“Effective Date” means October 8, 2020.
(t)
“Employee” means any person providing services as an employee of the Company or an Affiliate. However, service
solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for
purposes of this Plan.
(u)
“Entity” means a corporation, partnership, limited liability company or other entity.
(v)
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.
(w)
“Exchange Act Person” means any natural person, Entity or “group” (within the meaning of Section
13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary
of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding
securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities
pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the
Company in substantially the same proportions as their Ownership of stock of the Company, or (v) any natural person, Entity or “group”
(within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly,
of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities.
(x)
“Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:
(i)
If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a
share of Common Stock as of any date of determination will be, unless otherwise determined by the Board, the closing sales price for such
stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the
date of determination, as reported in a source the Board deems reliable.
(ii)
Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then
the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.
(iii)
In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in
a manner that complies with Sections 409A and 422 of the Code.
(y)
“Incentive Stock Option” means an option granted pursuant to Section 5 of this Plan that is intended
to be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.
(z)
“Non-Employee Director” means a Director who either (i) is not a current employee or officer of the Company
or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered
as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item
404(a) of Regulation S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest
in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business
relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee
director” for purposes of Rule 16b-3 of the Exchange Act.
(aa)
“Nonstatutory Stock Option” means any option granted pursuant to Section 5 of this Plan that does not
qualify as an Incentive Stock Option.
(bb)
“Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.
(cc)
“Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted
pursuant to this Plan.
(dd)
“Option Agreement” means an Award Document evidencing the terms and conditions of an Option grant. Each Option
Agreement will be subject to the terms and conditions of this Plan.
(ee)
“Optionholder” means a person to whom an Option is granted pursuant to this Plan or, if applicable, such other
person who holds an outstanding Option.
(ff)
“Own,” “Owned,” “Owner,” “Ownership” means a person
or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership”
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise,
has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.
(gg)
“Participant” means a person to whom an Award is granted pursuant to this Plan or, if applicable, such other
person who holds an outstanding Stock Award.
(hh)
“Performance Cash Award” means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).
(ii)
“Performance Period” means the period of time selected by the Board over which the attainment of one or more
performance goals will be measured for the purpose of determining a Participant’s right to and the payment of a Stock Award or a
Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.
(jj)
“Performance Stock Award” means a Stock Award granted under the terms and conditions of Section 6(c)(i).
(kk)
“Plan” means this 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, as amended and restated from time
to time.
(ll)
“Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms and
conditions of Section 6(a).
(mm)
“Restricted Stock Award Document” means an Award Document evidencing the terms and conditions of a Restricted
Stock Award grant. Each Restricted Stock Award Document will be subject to the terms and conditions of this Plan.
(nn)
“Restricted Stock Unit Award” means a right to receive shares of Common Stock which is granted pursuant to the
terms and conditions of Section 6(b).
(oo)
“Restricted Stock Unit Award Document” means an Award Document evidencing the terms and conditions of a Restricted
Stock Unit Award grant. Each Restricted Stock Unit Award Document will be subject to the terms and conditions of this Plan.
(pp)
“Securities Act” means the U.S. Securities Act of 1933, as amended.
(qq)
“Stock Appreciation Right” or “SAR” means a right to receive the appreciation on Common Stock
that is granted pursuant to the terms and conditions of Section 5.
(rr)
“Stock Appreciation Right Award Document” means an Award Document evidencing the terms and conditions of a Stock
Appreciation Right grant. Each Stock Appreciation Right Award Document will be subject to the terms and conditions of this Plan.
(ss)
“Stock Award” means any right to receive Common Stock granted under this Plan, including an Incentive Stock
Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, or a Performance
Stock Award.
(tt)
“Stock Award Document” means an Award Document evidencing the terms and conditions of a Stock Award grant. Each
Stock Award Document will be subject to the terms and conditions of this Plan.
(uu)
“Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding
capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether,
at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of
any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or
other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital
contribution) of more than 50%.
(vv)
“Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code)
stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.
01 - Robert J. Bitterman 04 - Jonathan E. Freeman, Ph.D. 02 - Patricia A. Bradford 05 - Curtis A. Lockshin, Ph.D 03 - Robert L. Ferrara For Withhold For Withhold For Withhold 1 U P X Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 03TYXB + + Proposals — The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2 and 3. A 2. Ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. 1. Election of Directors: For Against Abstain Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. Authorized Signatures — This section must be completed for your vote to count. Please date and sign below. B T IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. T Annual Meeting Proxy Card 1234 5678 9012 345 3. To approve an amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 125,000. For Against Abstain MMMMMMMMM 5 8 0 0 5 2 MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND C 1234567890 J N T MMMMMMMMMMMM MMMMMMMMMMMMMM MMMMMM If no electronic voting, delete QR code and control # Δ ≈ 000001 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE SACKPACK C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext Your vote matters – here’s how to vote! You may vote online or by phone instead of mailing this card. Online Go to www.envisionreports.com/PHIO or scan the QR code — login details are located in the shaded bar below. Phone Call toll free 1 - 800 - 652 - VOTE (8683) within the USA, US territories and Canada Save paper, time and money! Sign up for electronic delivery at www.envisionreports.com/PHIO
Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/PHIO Phio Pharmaceuticals Corp. Annual Meeting of Stockholders July 20, 2023 9:00 a.m. Eastern Time This proxy is solicited by the Board of Directors The undersigned hereby constitutes and appoints Robert J . Bitterman and Caitlin Kontulis as proxies, with the full power of substitution in each of them . Each of them is hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the virtual Annual Meeting of Stockholders of Phio Pharmaceuticals Corp . to be held on July 20 , 2023 , or at any postponement or adjournment thereof, on all matters set forth on the reverse side and in the discretion of the proxies upon such other matters as may properly come before the meeting . Shares represented by this proxy will be voted by the stockholder . If no such directions are indicated, the Proxies will have authority to vote FOR the election of the Board of Directors and FOR items 2 and 3 . (Items to be voted appear on reverse side) Proxy / Voting Instruction Card T IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. T Change of Address — Please print new address below. Comments — Please print your comments below. Non - Voting Items C + + The 2023 Annual Meeting of Stockholders of Phio Pharmaceuticals Corp. will be held on July 20, 2023 at 9:00 a.m. Eastern Time, virtually via the internet at meetnow.global/MQKLG2L. To access the virtual meeting, you must have the 15 - digit code that is printed in the shaded bar located on the reverse side of this form.
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Aug 2023 to Aug 2024